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1. Abstract 
 
Background: Cholecystectomy is used for the management and prevention of 
gallbladder stones and poses a major burden on healthcare resources. Obesity and 
rapid weight loss are known risk factors for gallstones, the prevalence of which is 
rising given the obesity epidemic. We conducted a Cochrane systematic review and 
meta-analysis of randomised controlled trials to evaluate the efficacy of using non-
surgical interventions for the primary prevention of gallbladder stones in high risk 
adults. 
Methods: Electronic searches (Cochrane Library, CENTRAL, Medline, Embase, and 
Science Citation Index Expanded) and manual searches (up to July 2013) were 
carried out with no restrictions on publication status or language. The intervention 
comparisons included pharmacological (ursodeoxycholic acid, UDCA) or non-
pharmacological (high-fat weight loss diet) versus control interventions (placebo, no 
intervention, fibre supplement or low-fat weight loss diet). Random-effects meta-
analyses were performed and intertrial heterogeneity and bias was evaluated with 
subgroup, sensitivity, regression, and sequential analysis.  
Results: Overall, 14 trials comprising a total of 1,942 participants undergoing weight 
loss through dieting, or after bariatric surgery (13 trials); or participants following 
cardiac surgery (one trial) were included. UDCA reduced the risk of ultrasonically 
verified gallstones compared with control interventions (risk ratio (RR) 0.32, 95% 
confidence interval (CI) 0.19 to 0.55, I2=60%). UDCA was more beneficial in 
participants undergoing weight loss through diet alone (RR 0.17, 95% CI 0.11 to 
0.25, I2=0%) than after bariatric surgery (RR 0.42, 95% CI 0.21 to 0.83, I2=64%). Two 
trials found that high dietary fat content reduced the formation of gallstones during 
weight loss achieved through low calorie diets (RR 0.09, 95% CI 0.01 to 0.61, 
I2=0%). Regression analysis showed no evidence of small study effects. No 
additional beneficial or harmful effects on remaining outcomes were identified. 
Conclusions: These results suggest that during weight loss UDCA and high dietary 
fat content may prevent formation of gallstones. Beneficial mechanistic effects may 
include enhanced gallbladder motility. The above prevention strategies could 
represent cost-effective alternatives to cholecystectomy.     
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Hintergrund: Für die Prävention und Behandlung von Gallensteinen wird die 
Cholezystektomie eingesetzt. Sie stellt eine erhebliche Kostenbelastung für das 
Gesundheitswesen dar. Adipositas und schnelle Gewichtsabnahme sind 
Risikofaktoren für Gallensteine, und die Prävalenz von Gallensteinen steigt durch die 
Adipositas-Epidemie. Ziel dieser Arbeit war es, ein systematisches Cochrane Review 
und eine Meta-Analyse von randomisierten kontrollierten Studien durchzuführen, um 
die Wirksamkeit von nicht-chirurgischen Eingriffen zur primären Prävention von 
Gallensteinen bei Patientengruppen mit hohem Risiko zu bewerten. 
Methode: Elektronische Recherchen (Cochrane Library, CENTRAL, MEDLINE, 
EMBASE und Science Citation Index Expanded) und manuelle Literaturstudien (bis 
einschließlich Juli 2013) wurden ohne  Einschränkungen bezüglich 
Publikationsstatus oder Sprache durchgeführt. Diese Interventionen setzten sich aus 
pharmakologischen (Ursodeoxycholsäure, UDCA) und nicht-pharmakologischen 
(fettsupplementierte Diäten zur Gewichtsabnahme) versus Kontroll-Interventionen 
(Plazebo, keine Intervention, Ballaststoff-Ergänzung oder fettarme Diäten zur 
Gewichtsabnahme) zusammen. Random-Effects-Meta-Analysen wurden 
durchgeführt und Intertrial-Heterogenität und Bias wurden mit Subgruppen-, 
Sensitivitäts-, Regressions- und Sequenz-Analysen ausgewertet. 
Ergebnisse: Es wurden insgesamt 14 Studien mit 1.942 Teilnehmer eingeschlossen. 
Die Teilnehmer erzielten die Gewichtsabnahme durch Diät oder bariatrische 
Chirurgie (13 Studien) oder unterzogen sich einer kardiochirurgischen Operation (1 
Studie). Die UDCA-Intervention reduzierte das Risiko von Gallensteinen im Vergleich 
zur Kontrollgruppe (Risiko-Verhältnis (RR) 0,32, 95%-Konfidenzintervall (CI) 0,19 - 
0,55, I2=60%). UDCA war effektiver, wenn der Gewichtsverlust durch Diät allein 
erreicht wurde (RR 0,17, 95%-CI 0,11 - 0,25, I2=0%) als nach Adipositaschirurgie 
(RR 0,42, 95%-CI 0,21 bis 0,83, I2=64%). Zwei Studien legen nahe, dass fettreiche, 
kalorienarme Diäten zur Gewichtsabnahme die Inzidenz von Gallensteinen 
reduzieren (RR 0,09, 95%-CI 0,01-0,61, I2=0%). Es wurden keine weitere 
vorteilhaften Effekte oder unerwünschte Wirkungen identifiziert. 
Fazit: Die Ergebnisse der Meta-Analyse legen nahe, dass UDCA sowie 
fettsupplementierte kalorienarme Diäten das Risiko von Gallensteinen, während einer 
Gewichtsreduktion reduzieren. Diese Präventionsstrategien stellen kostengünstige 
Alternativen zur Cholezystektomie beim Gallensteinleiden dar. 
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2. Introduction   
 
The prevalence of gallstones is currently between 10% and 20% in Western adults, 
with a projected rise given the increasing ageing population and obesity epidemic.55 
98 243
 Over 30% of Americans are now obese,76 but the United States is not alone in 
their rising obesity rates, since recent statistics also report 67 and 53% of men and 
women in Germany are overweight and 23% and 24% are obese, respectively.66 
Additionally, 65% of men and 58% of women in England are overweight or obese, 
and 31% and 28% of boys and girls, respectively.82 A longitudinal study comprising 
90,302 women reported a sevenfold risk of gallstones in morbidly obese compared to 
normal weight populations.202 Moreover, a recent study in 77,679 Danish individuals 
reported a causal association between elevated BMI and increased risk of 
symptomatic gallstone disease.203 A recent multi-ethnic population based cross-
sectional study in the United States106 reported 766 children between the ages of 10 
to 19 to have gallstones. The risk was substantially higher for the extreme obese.  
Gallstones are predominantly asymptomatic, however, an estimated 25% of stone 
carriers develop symptoms and complications such as cholecystitis, cholangitis, and 
pancreatitis.63 Patients with symptomatic gallbladder stones frequently require 
hospital admission and laparoscopic cholecystectomy. Non-surgical options for 
preventing gallstones are currently underused, and over 50,000 cholecystectomies 
are performed each year in the United Kingdom, of which over 90% are carried out in 
the National Health Service (NHS).21 194 Germany and the United States surpass this 
rate with approximately 170,000 and 700,000 cholecystectomies per year, 
respectively.53 117 This corresponds to a substantial burden on healthcare resources.  
This burden may be further compounded by some negative outcomes that have been 
linked to cholecystectomy. In particular, cholecystectomy is associated with a 1.6% 
risk of damage to the bile ducts and a 0.5% mortality risk.1 In addition obese patients 
undergoing gastric bypass surgery with concomitant cholecystectomy often require 
longer hospital stays and have a risk of post-operative complications.73 Prophylactic 
cholecystectomy is proposed for these individuals due to the high risk of developing 
symptomatic gallstones following rapid weight loss,129 although the risk of developing 
symptoms might actually be moderate.90 Prophylactic cholecystectomy is 
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contraindicated in certain situations, such as post-cardiac surgery patients who have 
an increased risk of gallstones.15 100 A Cochrane review reported symptom 
recurrence in up to 40% of post-cholecystectomised patients.97 In fact, post-
cholecystectomy syndrome is reported in 5 to 47% of patients31 88 and includes a 
wide range of symptoms (biliary and extra-biliary) and is often characterised by pre-
surgery symptom recurrence. 
Once a person has been cholecystectomised, there is a continual flow of bile to the 
duodenum which consequently increases the production of secondary bile acids 
(deoxycholic and lithocholic acid). This occurs as a result of an increased 
enterohepatic circulation and subsequent degradation by intestinal gut bacteria of the 
primary bile acids. It has been suspected, that secondary bile acids elicit 
carcinogenic effects. Lagergren et al.113  reported an increased risk of intestinal 
cancer following cholecystectomy. More recently, the same authors reported a weak 
association between oesophageal adenocarcinoma and patients with 
cholecystectomy.114 Though confounders, such as obesity were not controlled for in 
the study, this observed association could be attributed to increased concentrations 
of bile in gastric fluid, which consequently may come into contact with the 
oesophagus during gastro-oesophageal reflux. The study also found an association 
between hepatocellular carcinoma and cholecystectomy.115 In contrast, other studies 
do not report an increased cancer risk after cholecystectomy, as illustrated in a meta-
analysis by Zhao et al.260 Therefore, the potential carcinogenic effects have yet to be 
fully substantiated. 
 
2.1 Pathobiology  
 
Gallstones are essentially made up of cholesterol crystals, mucin, calcium, 
bilirubinate and proteins which precipitate to form biliary sludge and subsequently 
gallstones. The ratio of these components determines which of three categories the 
stones belong to. Cholesterol gallstones comprise > 90% of cases and consist 
primarily of cholesterol monohydrate crystals, whereas the main component of black 
and brown pigment stones is calcium bilirubinate (Table 1).182 The prevalence of 
cholesterol stones is much higher than either black or brown pigment stones. 
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The formation of gallstones involves the liver, gallbladder and intestine and the 
detailed pathobiology of gallstones has been summarized in one of our previous 
reviews.209 There are three fundamental steps that lead to gallstone formation:  
1. Excess cholesterol and/or bilirubin cannot be solubilized by mixed micelles 
and lead to the supersaturation of bile, 
2. gallbladder hypomotility, 
3. destabilisation of bile through proteins offsetting the crystallization sequences.   
 
 
       Table 1.  Classification of gallstones 
 
 
Cholesterol stones  
 
Black 
pigment stones 
Brown 
pigment stones 
 
Main 
Composition 
 
 
Cholesterol 
monohydrate 
 
Bilirubin polymers  
+ Calcium 
 
Calcium  
bilirubinate  
 
Location Gallbladder Gallbladder Infected bile ducts 
Prevalence 
> 90% ~2% ~10% 
        
        Adapted from Stokes et al.208  
 
The pathobiological process is as follows: adenosine triphosphate (ATP)-dependent 
transport proteins, referred to as ATP-binding cassette canalicular transporters (ABC 
transporters) secrete biliary lipids into bile; unilamellar vesicles (composed of 
phosphatidylcholine and cholesterol) and simple micelles (composed of bile salts and 
cholesterol) form. Whilst they are channeled through the biliary tract and into the 
gallbladder, they are converted into mixed micelles. If these mixed micelles are 
challenged with more cholesterol in bile than they can solubilise (indicated by a 
cholesterol saturation index (CSI) > one), then cholesterol-rich multilamellar vesicles 
(liquid crystals) form. The aggregation of these multilamellar vesicles precedes the 
formation of solid cholesterol crystals. 
The physical-chemical composition of bile plays a fundamental role in the formation 
of gallstones and the balance of biliary lipid concentrations (bile salts, bilirubin, 
_________________________________________________________________________ 
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cholesterol and phospholipids) determines the extent of solubility of biliary cholesterol 
and bilirubin. When bile becomes supersaturated with cholesterol, this is on account 
of an increased ratio of cholesterol and/or bilirubin to bile salts or phospholipids. It is 
usually due to cholesterol hypersecretion or the hyposecretion of bile salts and/or 
phospholipids.137 Intestinal hypomotility increases the bacterial colonic formation of 
the secondary bile salt, deoxycholate, which leads to more lithogenic bile thus 
causing gallstones. In fact, slow intestinal transit and increased deoxycholate are 
commonly reported in patients with cholesterol gallstones.170 Figure 1 depicts the 
aforementioned pathophysiological events in cholesterol gallstone formation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pathophysiology of cholesterol gallstone formation. Reproduced with permission from 
Portincasa et al.171  Copyright © 2006 Elsevier Ltd 
 
 
 
 
 
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 16 
2.2 Environmental and genetic risk factors 
 
2.2.1 Genetic factors  
 
The disparity in gallstones amongst different ethnic groups points to a strong genetic 
propensity to form gallstones.110 In fact, gallstone susceptibility ‘thrifty’ genes are 
suggested to have evolved during the Great Ice Age.38 Genetic factors account for 
25% of the risk in Europeans.95 Moreover, gallstones form more frequently (i.e. the 
risk is five-fold) in those with a family history of gallstones.13 Genetic risk is 
dependent on the type of mutations, for example in monogenic mutations (such as 
ABCB4) gallstones are a result of a strong genetic component,108 however a stronger 
environmental influence is observed in carriers of common risk variants, hence 
gallstones are often an end result of higher order interactions between multiple 
genetic and lifestyle determinants.208  
Numerous candidate Lithogenic (LITH) genes such as the common ABCG8 mutation 
p.D19H, which increases hepatobiliary cholesterol efflux, confer an increased risk of 
gallstones.109 This genetic risk is amplified with certain environmental factors. 
Genetic variants such as the ABCG5/8 variants do not fully explain this increased 
genetic risk, however the transport activity of these proteins (cholesterol 
hemitransporter) may be amplified, thus increasing the risk of gallstones. Twin 
studies actually show genetic risk factors to account for 25% of total risk and 
environmental factors for 75%.96 
The increased prevalence of gallstones has been illustrated in geographically and 
ethnically disparate locations in which stark differences in dietary intake are 
apparent.206 The composition of gallstones in Native Americans, post-war European 
countries and East Asian countries differs, and cholesterol gallstones are more 
prevalent in regions that have adopted ‘Westernized’ dietary habits, thus illustrating a 
strong dietary influence.159 Dietary and other environmental risk factors (summarised 
in Table 2) are discussed in more detail below, and are based on our previous 
publication reviewing risk factors for gallstones.208 
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Table 2.  Summary of major risk factors for gallbladder stones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Stokes et al.208 
HDL-C, High Density Lipoprotein Cholesterol; HRT, Hormone Replacement Therapy;  
MS, Metabolic Syndrome; SCI, Spinal Cord Injury; TG, Triglycerides 
 
 
 
 
  
Risk Factors Cholesterol 
stones 
Black pigment 
stones 
Family history (genetics) / ethnicity   
Increasing age   
Female gender, parity   
Obesity, especially central adiposity   
Rapid weight loss / bariatric surgery   
Physical inactivity    
Diet  High calorie / carbohydrate / glycaemic load 
         Low fibre 
        
  
MS   Dyslipidaemia (↑ TG,↓ HDL-C)   
        Insulin resistance, diabetes 
 
  
Vitamin B12 and folic acid deficiency 
 
 
Prolonged total parenteral nutrition   
Drugs Estrogen therapy (HRT) 
           Somatostatin analogue-octreotide 
           Calcineurin inhibitors 
           Fibrates 
  
SCI  
 
Crohn’s disease    
Cystic fibrosis    
Surgery Gastrectomy   
Ileal resections 
 
 
Anaemia (haemolytic, sickle cell)   
Liver cirrhosis   
Chronic Hepatitis C Virus infection   
 
Enterohepatic bacteria (Helicobacter spp.)                         
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2.2.2 Diet and other lifestyle factors 
2.2.2.1 Macronutrients 
 
A ‘Westernized’ diet usually comprises a high-caloric, high-carbohydrate, low fibre 
and generally a nutrient-depleted diet. Of note, large epidemiological studies from the 
US, Europe, Japan, and China report these dietary aspects as risk factors for 
cholesterol gallstones.223 224 226-228 234 A high carbohydrate diet and a concomitant 
high glycaemic load increased symptomatic gallstone risk, as well as 
cholecystectomy in two large US prospective epidemiological association studies 
using cohorts from the Health Professionals Follow-up Study (men) and the Nurses’ 
Health Study (women).226 227 In particular, two cohorts also reported a specific 
increased risk of gallstones with refined sugar consumption, a finding commonly 
reported by others.8 143 145 186 Interestingly, fibre consumption, particularly long-term 
intake has been linked to a reduced risk of gallstones, and conversely low fibre intake 
is purported to be a risk factor for stone formation.14 93 132 143 192 223 
Given the clear association between a typical Western diet and gallstones, the 
question of how nutrients encourage cholelithiasis begs asking. High caloric 
consumption may indirectly increase this risk through instigating obesogenic effects. 
Of note, obesity is an established risk factor and is discussed below. Moreover, a 
fibre-depleted, calorie rich diet increases biliary cholesterol secretion and slows 
intestinal transit, which has been reported in patients with gallstones.74 A high-fibre 
diet therefore, may accelerate intestinal transit, and exert its protective effects as this 
reduces not only constipation, but also deoxycholate formation (known to increase 
the cholesterol saturation of bile).133 Animal studies have demonstrated these 
beneficial effects of fibre. Specifically, Schwesinger et al.183 partially suppressed 
cholesterol gallstone formation in a prairie dog model by adding soluble fibre (as 
psyllium) to a diet consisting of 1.2% cholesterol. A high carbohydrate, high 
glycaemic load diet may trigger gallstone development indirectly through lipid-related 
alternations, such as raised plasma triglycerides (TG) and reduced high density 
lipoprotein cholesterol (HDL-C). It may also lead to exacerbations of insulin 
resistance and of other conditions of the metabolic syndrome, also linked to gallstone 
incidence. Elevated hepatic cholesterol synthesis and increased bile salt 
_________________________________________________________________________ 
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malabsorption via hepatic insulin resistance may follow,28 all of which are risk factors 
for gallstones.116  
The role of lipids in gallstone formation is to date inconclusive.45 In broad terms, 
saturated and trans fatty acids have been associated with an increased risk in 
prospective follow-up studies.225 231 In contrast, poly- and monounsaturated fatty 
acids have been linked to a decreased risk.222 Dietary cholesterol is of particular 
interest, given the inherent role of cholesterol in gallstone formation. Experimental as 
well as human studies (of observational and interventional nature) report mixed 
results when evaluating the association between high cholesterol diets and 
gallstones risk.120 158 These discrepancies may be attributed to innate differences in 
lipid metabolism - a concept that is further supported by studies reporting a genetic 
influence on lipid metabolism, such as the ABCG8 genes that determine dietary 
cholesterol absorption.25 
 
2.2.2.2 Micronutrients  
 
A decreased prevalence of ultrasonographically identified gallstones was detected in 
a population-based observation study with regular vitamin C supplementation (Odds 
Ratio [OR] 0.34, 95% CI 0.14 to 0.81, p<0.01).244 This finding has been documented 
in other studies and appears to be more prominent in women as opposed to men.89 
193
 This protective influence may occur through the mediative effects of cholesterol 
7α-hydroxylase activity (the rate-limiting enzyme in bile acid synthesis), which is 
reduced by ascorbic acid, as is cholesterol catabolism in bile, accordingly.  
Moreover, a protective association was also observed with dietary magnesium intake 
in a large prospective cohort with the relationship being independent, and dose-
responsive (Relative Risk [RR] 0.68, 95% CI 0.57 to 0.82, p<0.001).230 A magnesium 
deficiency has not only been related to insulin resistance and diabetes but also to 
raised plasma TG, low density lipoprotein cholesterol (LDL-C) and lower HDL-C 
levels.104 Reduced magnesium levels have also been linked to the metabolic 
syndrome;54 correspondingly, magnesium may improve insulin sensitivity and lipid 
profile and hence have a positive effect on gallstone risk. Additionally, magnesium 
may exert its protective effects through its influence on gallbladder contractions via 
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cholecystokinin (CCK) stimulation; however precise mechanistic effects remain to be 
established.  Finally, vitamin B12 and folic acid may influence gallstone formation, 
and these vitamins are discussed in another section. 
 
2.2.2.3 Alcohol 
 
The influence of alcohol consumption on gallstone risk remains controversial, as 
many studies have reported an inverse association between the two,14 123 126 245 
however, others have failed to observe any correlation.19 107 168 180 Völzke et al.243  
reported an OR of 0.77 (95% CI 0.54 to 1.09, p=0.14) in men consuming 0 - 20 g 
alcohol daily. These odds were further reduced when the daily intake was between 
20 - 60 g alcohol (OR 0.72, 95% CI 0.51 to 1.03, p=0.07) and were significantly 
reduced with > 60 g alcohol per day (OR 0.42, 95% CI 0.23 to 0.78, p<0.05). Alcohol 
consumption may reduce the CSI and increase HDL-C, thus inhibiting cholesterol 
stone formation.219 On the contrary, severe alcohol abuse will raise the risk of 
(pigment) gallstones by means of liver damage and reduced synthesis of bile salts. 
This has been illustrated in studies showing alcohol-related cirrhosis to be a strong 
independent risk factor for gallbladder stones.61 172  
 
2.2.2.4 Coffee 
 
As with alcohol consumption, large epidemiological studies assessing coffee intake 
and risk of gallstones report diverse results. Indeed, both significant and non-
significant inverse associations have been reported between coffee intake and 
incidence of gallstones.49 92 125 142 161  In contrast, there are also documented reports 
of no association between the two,112 180 245 or even an increased risk of gallstones 
with coffee consumption.19 87 243 One cannot be sure whether these discrepancies 
result from ethnic and/or complex gene-environment interactions, however caffeine 
and perhaps additional components in coffee might alter serum lipids and impact on 
enterohepatic bile salt circulation, thus reducing gallstone risk.  
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2.2.2.5 Physical inactivity 
 
Physical activity has been associated with a reduced risk of gallstones, in particular 
the symptomatic variety and hence with cholecystectomy. These associations have 
been illustrated in two large US cohorts,122 124 but also in a European cohort 
(European Prospective Investigation of Cancer (EPIC) cohort.18 Of note, findings 
from the European cohort suggest a 70% risk reduction of symptomatic gallstones 
could be achieved after five years in those who are physically active. In addition, 34% 
of symptomatic gallstones in men could possibly be prevented with 30 minutes of 
endurance exercise (i.e. running, cycling) if carried out five times per week.122 Altered 
hepatobiliary function could in theory be responsible for these beneficial effects of 
physical activity on gallstones. Moreover, physical activity not only enhances gut 
motility and increases bile acid excretion,165 249 but it can also raise HDL-C 50 via its 
influence on plasma TG and insulin release,102 220  all of which lower biliary 
cholesterol saturation. As such, a sedentary lifestyle will increase the risk not only of 
gallstones, but of the complications that can ensue.  
 
2.2.2.6 Metabolic syndrome 
 
The cluster of conditions belonging to the metabolic syndrome including 
dyslipidaemia (particularly hypertriglyceridaemia and low HDL-C), diabetes and 
insulin resistance/hyperinsulinaemia are all often co-morbid with gallstone disease, 
as such, they are suggested to be risk factors.188 232 243 In fact, a two-to-threefold 
higher prevalence of gallstones in insulin-resistant individuals and in those with type 
2 diabetes has been observed.179 A mouse model illustrated a molecular link 
between the metabolic syndrome and cholesterol gallstones via hepatic insulin 
resistance, and consequently increased biliary cholesterol secretion.28 Of note, 
increased hepatic cholesterol secretion, gallbladder dysmotility and supersaturated 
bile are all aggravated by the metabolic syndrome and this in turn may set the stage 
for subsequent gallstones formation.6 Interestingly, in societies that have adopted a 
‘Westernized’ diet, alarmingly high rates of the metabolic syndrome are also 
observed, as are gallstones.2 To this end, mutual common dietary risk factors are 
likely to increase the risk of both the metabolic syndrome and of gallstones.  
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2.2.2.7 Obesity  
 
Obesity could very well be the common denominator between diet and gallstone risk 
as it is part of the spectrum of the metabolic syndrome and it is a well-established risk 
factor for gallstones.243 Obesity promotes insulin resistance and biliary 
hypersecretion of cholesterol, leading to lithogenic bile.24 28 144 Interestingly, the type 
of adiposity is also reported to influence gallstone formation. Prospective cohort 
studies have reported a stronger association with central adiposity relative to limb or 
lower extremity adiposity, therefore regional fat distribution may further intensify 
stone risk.72 In fact, abdominal adiposity was associated with an increased risk of 
symptomatic gallstones and with cholecystectomy, independently of BMI in two US 
cohorts.224 228  
 
2.2.2.8 Rapid weight loss and/or surgery for obesity 
 
Paradoxically, not only is obesity linked to an increased risk of gallstones, but so is 
rapid weight loss, (i.e. > 1.5 kg per week), and/or weight loss greater than 25% body 
weight.127 191  These findings have been illustrated in studies where patients follow 
very low calorie diets and/or undergo bariatric surgery (e.g. Roux-en-Y gastric 
bypass).81 94 127 128 251 258 Specifically, a 13% gallstone incidence was observed after 
17 weeks in obese participants following a combined liquid and solid foods low-
calorie diet (925 kcal).201 Liddle et al.128 reported a 25% increased risk of gallstones 
when obese subjects followed a 2100 kJ (500 kcal) diet for eight weeks, and Li et 
al.127 found a ~30% increased risk post bariatric surgery. Of note, gallstones 
formation during rapid weight loss has been referred to as a possible adverse event, 
as such clinicians are obliged to inform patients of the risks.73 166  
Slower weight loss will reduce the risk of gallstones forming, however this weight loss 
must be sustained because weight cycling (i.e. weight that is lost and regained) also 
increases the risk of gallstones and this risk appears to be independent of body 
weight.229 Weight cycling not only correlates with gallstones, but also with its 
complications and might trigger symptomatic gallstones as data from a large cohort 
observed an increased risk of cholecystectomy in such subjects.214 Interestingly, this 
cohort illustrated a risk of 31% in women with at least one moderate weight cycle (4.5 
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 23 
- 8.5 kg), however this increased to 68% in subjects with severe weight fluctuations 
(≥ 9 kg). The reason for this observed risk is multifactorial and includes impaired 
gallbladder motility, and the consequent bile stasis and biliary sludge which follow. 
However, an altered ratio of cholesterol to bile salts in the gallbladder also results 
from rapid weight loss and weight cycling. This is due to the amplified cholesterol 
mobilisation from peripheral tissue, and the concomitant increased hepatic 
cholesterol synthesis.67 131 175  
 
2.2.3 Environmental factors   
 
2.2.3.1 Treatments / medication 
 
Prolonged total parenteral nutrition (TPN) can weaken gastrointestinal stimulation, 
thus impairing gallbladder emptying. This can cause bile stasis which predisposes to 
biliary sludge and eventually gallstones. The incidence of gallstones however – which 
reportedly can range from 20% to 75% – can be reduced with concomitant oral 
intake.10 70 There are several other conditions, such as spinal cord injury (SCI), that 
can lead to bile stasis.11 16 Of note, 30% of patients with SCI are reported to have 
gallstones, or to have undergone cholecystectomy.148  
Certain medications such as octreotide (a somatostatin analogue) can trigger bile 
stasis. In fact, reduced intestinal transit was observed in those taking octreotide, and 
this led to lithogenic bile salt pool formation and subsequent gallstone development. 
29
 
84
 Calcineurin inhibitors, namely ciclosporin and tacrolimus, can also cause 
gallstones via the inhibition of the hepatocanalicular bile salt export pump.139 205  
Furthermore, fibrates (cholesterol-lowering drugs) raise biliary cholesterol saturation 
and reduce bile salt synthesis, thus also increasing the risk of gallstones.196 In 
contrast however, some other types of cholesterol lowering drugs, (i.e. statins) 
decrease hepatic cholesterol biosynthesis and consequently reduce cholesterol 
concentrations in bile, and so might reduce the risk of gallstones as demonstrated in 
prospective follow-up and case-control studies.20 233 Interestingly, ezetimibe was 
shown in mouse models to exert its protective effect through the reduced absorption 
of intestinal cholesterol coupled with an increase in bile flow.246 262  
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Estrogens such as oral contraceptives and postmenopausal hormonal replacement 
therapy (HRT) significantly increase the risk of cholesterol gallstones and 
cholecystectomy.39 56 243 Innate estrogen levels are also aetiologically linked to 
gallstones, as women compared to men appear to have a heighted gallstone risk, in 
particular multiparous women. This may be because estrogen enhances hepatic 
lipoprotein uptake and increases hepatic cholesterol synthesis.56 247 Progesterone, 
another steroid hormone, impairs gallbladder contraction and reduces the rate of 
emptying, hence might also lead to stone formation.174  
 
2.2.3.2 Infections, metabolic diseases and surgical procedures 
 
Bile duct infections such as those from parasites (e.g. Clonorchis sinensis, 
Opisthorchis viverrini or Ascaris lumbricoides) can trigger brown pigment stone 
formation by means of bacterial β-glucuronidase which reverses soluble conjugated 
bilirubin back to its insoluble unconjugated form.188 Thus, brown pigment stones 
result due to the precipitation of bilirubin into calcium salts of long-chain fatty acids.118 
Moreover, cholesterol gallstones may result from increased colonic bacterial 
formation of deoxycholate which causes increased secretion and saturation of biliary 
cholesterol.27 153 Of note, the presence of enterohepatic Helicobacter species have 
been detected in bile and might possibly play a causal role in gallstone pathogenesis. 
137
 
197
 This was illustrated in an experimental study, where a very high prevalence of 
gallstones (80%) was found in C57L/J mice after infection with enterohepatic 
Helicobacter strains.136 Likewise, increased quantities of Gram-positive anaerobes 
and increased 7α-dehydroxylating activity were observed in the caecum of patients 
with gallstones compared to controls.217 
Infections such as the chronic hepatitis C virus (HCV) are also correlated with the 
presence of gallstones. A US cohort (NHANES III) comprising 13,465 participants 
observed an increased risk of gallstones (OR 3.2, 95% CI 1.08 to 9.45) and 
cholecystectomy (OR 4.57, 95% CI 1.57 to 13.27) in men with HCV compared to men 
without the virus.30 This risk does not appear to be gender specific, as other studies 
also report a heighted risk of gallstones with presence of HCV in both men and 
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women.3 212 Insulin resistance has been suggested as the causal link between the 
two conditions, because it is able to increase bile cholesterol saturation.3 Insulin 
resistance could emerge from the development of central obesity and liver steatosis.3 
44
 
52
  
In addition to HCV, liver cirrhosis is a well-documented risk factor for gallstones, 
particularly for black pigment stones.42 206  Abnormal gallbladder motility, bile salt 
malabsorption, coupled with a decreased synthesis of bile salts can initiate increased 
enterohepatic cycling of unconjugated bilirubin and eventually stone formation in the 
cirrhotic patient.241 This exact mechanistic effect is suggested as causal for black 
pigment stones in cystic fibrosis,241 and in patients with Crohn’s disease, particularly 
if accompanied by extended ileal resection.33 118 160 In fact, a vitamin B12 deficiency 
often occurs in ileal resections (as it is actively absorbed in the terminal ileum) and a 
deficiency of vitamin B12 (and folic acid) – both of which are required for generating 
red blood cells – may increase stone risk by exacerbating anaemia.51 Black pigment 
stones have been reported in people with blood disorders such as hemolytic and 
sickle cell anaemia.118 Other surgical procedures, such as total gastrectomy can 
increase gallstone formation, particularly when total gastrectomy is accompanied by 
lymph node dissection.105 Fukagawa et al.64 identified gallstones in 26% of 672 
patients following gastrectomy with lymph-node dissection. This increased risk may 
result from damage to the hepatic branch of the vagal nerves which diminishes 
gallbladder contractility. 
 
2.3 Lifestyle interventions purported to reduce the risk of gallstones 
Evidence exists in support of ‘Westernised’ lifestyle habits such as physical inactivity 
and high-calorie, high-carbohydrate and saturated fat diets, as well as low fibre intake 
to confer an increased risk of cholelithiasis and to promote LITH gene penetrance.206 
Rapid weight loss and weight cycling also increase formation of gallstones primarily 
due to gallbladder stasis and reduced biliary bile salt secretion.229 250 Lifestyle 
interventions such as dietary fat manipulation during low calorie dieting or physical 
activity have been investigated for gallstone prevention. Beneficial effects may result 
from increased intestinal motility.18 Moreover, clinical studies using bile acids, 
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especially the secondary bile acid ursodeoxycholic acid (UDCA) have been assessed 
during rapid weight loss, given their ability to enhance cholesterol solubility. A meta-
analysis of five randomised trials on UDCA for gallstones prevention post bariatric 
surgery reported a protective effect against gallstones.237 UDCA is able to decrease 
the lithogenicity of bile by reducing the intestinal absorption and biliary secretion of 
cholesterol as well as through shifting the phase separation of bile towards 
solubilisation in micelles and vesicles.35 146 181 Given its reported efficacy, UDCA may 
have great potential as a preventive agent against gallstones.  
 
2.4 Why is it important to meta-analyse non-surgical interventions? 
The American Medical Association has just declared obesity to be a disease 
requiring medical treatment and prevention.9 Childhood obesity is currently ~ 20% 
and there is a strong likelihood that obese children are likely to be obese in later life 
or will attempt weight loss at some stage.82 In fact, a rise in adolescent bariatric 
surgery has recently been reported.83 Given the burden associated with gallstones 
and the rise in both adult and childhood obesity, we anticipate an increase in 
individuals at risk of gallbladder stones and consequently an increase in healthcare 
costs. Successful non-surgical preventions may need greater consideration. 
However, most randomised controlled trials with non-pharmacological and 
pharmacological interventions include small sample sizes and their combined effect 
is unclear. We therefore conducted a Cochrane systematic review and meta-analysis 
of randomised controlled trials to investigate the efficacy of non-surgical preventive 
options for gallbladder stones in adults.  
 
2.5 Meta-analysis for evidence based medicine and the Cochrane Collaboration 
 
A meta-analysis is defined as the statistical synthesis of data from separate but 
similar studies to obtain a quantitative summary of the results from these 
independent studies. The goal of a meta-analysis is ultimately to estimate the true 
treatment effect with high accuracy, and allows one to assess for consistency across 
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individual studies. A systematic review that includes a meta-analysis of high quality 
(i.e. well conducted) homogenous randomised controlled trials is considered the 
highest quality evidence in evidence based medicine. A systematic review facilitates 
the process by identifying, appraising and synthesising the research and presenting it 
in a systematic yet meaningful manner. It serves to inform researchers, consumers, 
healthcare providers and policy makers.  
The Cochrane Collaboration is an international highly reputable organisation 
dedicated to evidence based medicine.  It was founded in 1993 and named in honour 
of Archie Cochrane, a British medical researcher whose work in the 1970s greatly 
influenced the conversion of epidemiology into a scientific discipline.242 In the 1980s 
Archie Cochrane was the first to refer to a systematic review of randomised 
controlled trials and encouraged the scientific discipline to endorse such a technique 
for delineating scientific evidence (http://www.cochrane.org/about-us/history). In 1992 
the first Cochrane centre was established in Oxford, UK which subsequently led to 
the creation of the Cochrane Collaboration.40 
To date there are 53 different Cochrane Review Groups, each with a specific disease 
focus. The aim of these review groups is to support the production of high quality 
systematic reviews and meta-analyses, which they do through established protocols 
and regulations. The Cochrane Handbook of Systematic Reviews79 guides the 
authors of systematic reviews. Authors wishing to perform a systematic review are 
first required to submit a title registration form to the respective review group with an 
expression of interest on the review they would like to conduct. In our case, our 
review group is the Cochrane Hepato-Biliary Group (http://hbg.cochrane.org/). Once 
this is approved, authors are required to submit a full protocol which is subject to 
peer-review. Upon acceptance of the final version of the protocol, this is then 
published and authors are permitted to conduct the full review. Our title registration 
form and our published protocol can be found at the end of this thesis.  
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3. Methods 
 
This systematic review and meta-analyses were performed according to a published 
protocol207 and followed the instructions in the Cochrane Handbook for Systematic 
Reviews of Interventions.68 79 The main objective was to evaluate the non-surgical 
primary prevention of gallbladder stones in adults.  
 
3.1 Types of studies  
 
We included randomised clinical trials irrespective of blinding, language, sample size, 
or publications status. Quasi-randomised trials and observational studies were only 
eligible for inclusion in the analyses of adverse events. 
 
3.2 Types of participants 
 
Adults (at least 18 years of age) of either gender were included irrespective of 
ethnicity. Participants were eligible for inclusion if they did not have gallbladder 
stones at baseline. Trials conducted in children where appraised in the search for 
data on harm.    
 
3.3 Types of interventions  
 
Trials were considered for inclusion when at least one study group was allocated to 
receive a non-pharmacological intervention or a pharmacological intervention. Orally 
administered non-pharmacological and pharmacological interventions were included 
irrespective of the dose or class of drug. The control groups were allocated to 
placebo, no intervention, or to non-pharmacological or pharmacological, 
interventions. The threshold for duration of therapy was set to a minimum of four 
weeks, as studies report gallstones to typically form after this time frame.67 128  
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3.4 Types of outcome measures   
 
All outcome measures were assessed, where possible, at the maximum duration of 
follow-up. 
 
3.4.1 Primary outcomes 
 
Based on the specifications provided in the Cochrane Hepato-Biliary Group module 
Gluud,68 the following primary outcome measures were included: 
1. Mortality (all-cause). 
2. Morbidity (formation of ultrasonically verified gallbladder stones and symptomatic 
gallbladder stones). 
3. Number and types of adverse events (using definitions specified by authors of 
included trials or based on The International Conference on Harmonisation Expert 
Working Group International).86 
 
3.4.2 Secondary outcomes 
 
1. Quality of life. 
2. Cholecystectomy. 
3. Bile lithogenicity (defined as changes in physiological parameters of bile 
composition indicative of an increased risk of gallstones, e.g. cholesterol 
saturation index (CSI),37 nucleation time for cholesterol crystal formation,80 or 
presence of cholesterol crystals). 
4. Weight loss (reduction in body weight assessed in kg or using the body mass 
index (BMI)). 
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3.5 Search strategy for identification of trials 
 
Eligible trials were identified through electronic and manual searches. Randomised 
clinical trials were included. Male and female adults were included irrespective of 
ethnicity. Participants were eligible for inclusion if they did not have gallbladder 
stones at baseline verified by ultrasonography. We searched the Cochrane Hepato-
Biliary Group Controlled Trials Register,68 the Cochrane Central Register of 
Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and 
Science Citation Index Expanded. The last search update was performed in July 
2013 (Appendix 1).  
Trial registries were scanned in two search portals: the US National Institutes of 
Health (www.clinicaltrials.gov) and the WHO International Clinical Trial Registry 
Platform (www.who.int/ictrp/search/en/). We originally planned to include unpublished 
trials, but no such trial was identified. The manual search comprised scanning 
reference lists of relevant papers.  
All references identified in the searches were reviewed and potentially eligible trials 
were listed and compared against the inclusion criteria. Excluded trials were listed 
with the reason for exclusion. The data was extracted using standardised data 
extraction forms (Appendix 2) from the Cochrane Center. These forms were slightly 
modified to suit this systematic review/meta-analysis. Authors of individual trials were 
contacted for any unclear or missing information. Two trials were translated into 
English before the data extraction.  
 
3.6 Assessment of bias  
 
Trials were assessed using the Cochrane Collaboration risk of bias tool.79 The 
following information was extracted for each trial by at least two authors and risk of 
bias for each domain was rated as low (unlikely to significantly influence the results), 
high (likely to significantly influence the results), or unclear:  
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3.6.1 Allocation sequence generation 
- Low risk of bias: sequence generation was achieved using computer random 
number generation or a random number table. Drawing lots, tossing a coin, 
shuffling cards, and throwing dice are adequate if performed by an independent 
research assistant not otherwise involved in the trial. 
- Uncertain risk of bias: the method of sequence generation was not specified. 
- High risk of bias: the sequence generation method was not random. 
 
3.6.2 Allocation concealment 
- Low risk of bias: the participant allocations could not have been foreseen in 
advance of, or during, enrolment. Allocation was controlled by a central and 
independent randomisation unit. The allocation sequence was unknown to the 
investigators (for example, if the allocation sequence was hidden in sequentially 
numbered, opaque, and sealed envelopes). 
- Uncertain risk of bias: the method used to conceal the allocation was not 
described so that intervention allocations may have been foreseen in advance of, 
or during, enrolment. 
- High risk of bias: the allocation sequence was likely to be known to the 
investigators who assigned the participants. 
 
3.6.3 Blinding of participants, personnel, and outcome assessors 
- Low risk of bias: blinding was performed adequately, or the assessment of 
outcomes was not likely to be influenced by lack of blinding. 
- Uncertain risk of bias: there was insufficient information to assess whether 
blinding was likely to induce bias on the results. 
- High risk of bias: no blinding or incomplete blinding, and the assessment of 
outcomes were likely to be influenced by lack of blinding. 
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3.6.4 Incomplete outcome data 
- Low risk of bias: missing data were unlikely to make treatment effects depart 
from plausible values. Sufficient methods, such as multiple imputations, have 
been employed to handle missing data. 
- Uncertain risk of bias: there was insufficient information to assess whether 
missing data in combination with the method used to handle missing data were 
likely to induce bias on the results. 
- High risk of bias: the results were likely to be biased due to missing data. 
 
3.6.5 Selective outcome reporting 
- Low risk of bias: all outcomes were pre-defined (for example, in a published 
protocol) and reported, or all clinically relevant and reasonably expected 
outcomes were reported. 
- Uncertain risk of bias: it is unclear whether all pre-defined and clinically relevant 
and reasonably expected outcomes were reported. 
- High risk of bias: one or more clinically relevant and reasonably expected 
outcomes were not reported, and data on these outcomes were likely to have 
been recorded. 
 
3.6.6 Other biases 
- Low risk of bias: The study appears to be free of other sources of bias. 
- High risk of bias: There is at least one important risk of bias. For example, the 
study: had a potential source of bias related to the specific study design used; or 
has been claimed to have been fraudulent; or had some other problem. 
- Unclear risk’ of bias: There may be a risk of bias, but there is either: insufficient 
information to assess whether an important risk of bias exists; or insufficient 
rationale or evidence that an identified problem will introduce bias. 
- Inappropriate influence of funders (or, more generally, of people with a vested 
interest in the results) is often regarded as an important risk of bias: information 
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about vested interests was collected and presented in the ‘Characteristics of 
included studies’ table. The ‘Risk of bias’ table was used to assess specific 
aspects of methodology that might have been influenced by vested interests and 
which may lead directly to a risk of bias.   
 
3.7 Statistical analysis 
 
The data was analysed using the Cochrane Review software, Review Manager 5, 
STATA 12 (Stata Corp. Texas, USA) and Trial Sequential Analysis (Copenhagen 
Trial Unit, Copenhagen, Denmark). The primary meta-analyses were performed 
using random effects models due to expected clinical heterogeneity. Different 
interventions were analysed separately. Fixed effect models were used to evaluate 
the robustness of the results but were only reported if they differed from that of the 
random effects models. The measures of treatment effect were expressed as risk 
ratios for dichotomous data and weighted mean differences for continuous outcomes, 
both with 95% confidence intervals and with I2 as markers of heterogeneity. Based on 
the I2 values, heterogeneity was classed as not important (< 40%), moderate (40% to 
60%), substantial (> 60% to 75%) or considerable (> 75%). The number needed to 
treat (NNT) was computed for dichotomous data when the confidence interval did not 
cross one. When trials included more than two intervention groups, multiple groups 
were combined to create a single pair-wise comparison.79 Data on all participants 
randomised were sought to allow intention-to-treat analyses including all participants, 
irrespective of compliance or follow-up. 
 
3.7.1 Subgroup analysis and investigation of heterogeneity 
 
The risk of small study effects was analysed through regression analyses (Egger's 
test). We performed the following subgroup analyses to evaluate the influence of: 
participant type (type of weight loss method); treatment dose (medium-to-high or low 
dose UDCA, i.e. 1000 - 1200 mg or 500 - 750 mg, respectively); and risk of bias (low 
versus high or unclear risk of bias).  
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3.7.2 Sensitivity analysis 
 
Sensitivity analyses evaluated the importance of losses to follow-up (good outcome 
analyses assuming that losses to follow-up were treatment successes and poor 
outcome analyses assuming that losses to follow-up were treatment failures). We 
also repeated the analyses using the 0.5 continuity correction. This provides imputed 
data for analysis in trials reporting zero events in both arms, which comprised two 
trials in our meta-analyses.134 140 The results of these analyses are only reported if 
the conclusions differed from the primary analyses.  
 
3.7.3 Trial sequential analysis 
 
Cumulative meta-analyses are at risk of producing random errors due to sparse data 
and multiple testing.17 34 218 252 Therefore, sequential analysis was performed to 
assess the robustness of the data.43 The required information size was defined as 
the number of participants needed to detect or reject an intervention effect, and was 
estimated based on the event proportion in the control group, the observed relative 
risk reduction, and the diversity of the meta-analysis.252 253 The alpha was set to 5% 
and the power to 80%. On the basis of the required information size, trial sequential 
monitoring boundaries were constructed. Firm evidence was defined as being 
established if the sequential monitoring boundary was crossed before reaching the 
required information size. If the boundary was not crossed, the evidence was not 
conclusive. 
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4. Results  
 
Overall, we identified 3,044 references through our electronic searches and 17 
references through manual searches (Figure 2). No unpublished trials were identified 
through correspondence with pharmaceutical companies (Aptalis, Astellas, Bristol-
Myers Squibb, Consolidated Chemicals Ltd., Eli Lilly, Falk Pharma, Hoechst Marion 
Roussel, Johnson and Johnson, Lunbeck, Norgine Pharmaceuticals, Novartis, Pfizer, 
and Sanofi-Aventis).  
 
 
 
 
 
 
Figure 2.  Flow chart for the identification and selection of included randomised trials 
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Of note, one trial had to be excluded from our quantitative analysis because we were 
unable to extract data on the outcome measures.81 Therefore, after excluding this 
trial, the duplicates and references that did not refer to trials that fulfilled our inclusion 
criteria, 19 references (corresponding to 17 trials) were eligible for the qualitative data 
synthesis. Fifteen references (corresponding to 14 trials) fulfilled our inclusion criteria 
for the meta-analyses. Appendix 3 summarises the excluded trials, together with the 
reason for exclusion.  
 
4.1 Included studies  
4.1.1 Characteristics  
 
Two trials were multicentre in design,191 213 and the remaining were single centred. 
The trials were all published as full paper articles from 1988 to 2003. One trial was 
published in Italian47 and another trial in Spanish,149 which also included a short 
publication in English.150 The remaining trials were English language papers. 
Gallstones were diagnosed by ultrasonography. One trial used additional 
cholecystography254 and another trial used abdominal computerised tomography 
scans.141  
 
4.1.2 Participants 
 
Thirteen trials investigated obese participants (defined as BMI > 30 kg/m2) about to 
embark on weight loss. The majority of participants were female (range 42 - 100%). 
Eight of these trials used caloric restriction (details summarised in Table 3) based on 
a low-calorie (LCD: 900 - 1679 kcal/day) or very low-calorie diet (VLCD: < 800 
kcal/day) for weight loss. The remaining five trials assessed weight loss post bariatric 
surgery. Finally, one trial evaluated participants after major cardiac surgery.5  
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Table 3.  Dietary composition of weight loss diets 
Trial  kcal Protein 
(g) 
Carbohydrates  
(g) 
Fat 
(g) 
Fibre 
(g) 
Cholesterol 
(mg) 
Broomfield35 520 55 79 1   
De Filippo47 1000-1200 60-70 100-170 20-43 35-40 165-220 
Festi57        Intervention 
                   Control 
577 55 61.7 12.2   
535.2 44.4 82.2 3   
Gebhard67  Intervention 
                   Control 
900 90 68 30  90 
520 50 76 < 2  30 
Marks134 520 NG NG NG   
Mendez-Sanchez140 1200 60 180 27   
Moran149 150 1679* 67 248 48 20  
Shiffman191 520 50 79 1-3   
 
Abbreviations: NG, not given 
*Each patient had to reduce their total energy intake by 500 kcal and was instructed to follow a diet 
with 15% protein, 60% carbohydrate, 25% fat, as specified above.  
 
4.1.3 Interventions 
 
Two of these 14 trials compared 12 weeks of a high-fat modification weight reducing 
diet versus low-fat modification weight reducing diet.57 67 The diet in the intervention 
and control groups included 12.2 g versus 3.0 g fat57 or 30 g versus 2 g fat per day.67 
Twelve trials assessed 300 to 1200 mg/day UDCA (median 750 mg/day). The 
duration of treatment ranged between six weeks to 18 months, and the duration of 
follow-up ranged from six weeks to 60 months. Two trials included three different 
doses of UDCA: 300/600/1200 mg.191 213 Four trials included a third allocation arm in 
which participants received 1300 mg/day of acetylsalicylic acid (aspirin),35 1600 and 
600 mg/day of ibuprofen, respectively,134 257 or 11.3 g/day of omega-3 fatty acids.140 
Table 4 summarises the main characteristics of the included studies and the full 
details extracted for each study are in appendix 4. 
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Table 4 Characteristics of randomised controlled trials of non-surgical interventions for primary gallbladder stone prevention  
Trial Country Patients    
(n) 
Intervention  
(dose/day) 
Intervention 
duration (wks) 
Follow-up  
(wks) 
Baseline 
weight (kg) 
Mean weight 
lost (kg) 
Percentage 
weight lost 
Drop outs (excl 
withdrawals) 
Main inclusion criteria 
 
Ai5 Japan 52 54 
600 mg UDCA;  
control 24 240 
 
- - 
 15 
14 
Non-obese  
(post cardiac surgery) 
Broomfield35 USA 
23 
22 
23 
VLCD + 1200  mg UDCA; 
VLCD + 1300 mg aspirin; 
VLCD placebo 
16 19 
106 
98 
106 
21 
25 
21 
20 
26 
20 
5 
8 
4 
Obese 
 
De Filippo47 
 
Italy 20 20 
LCD + 600 mg UDCA; 
LCD + placebo 16 16 
105 
101 
10 
8 
10 
8 
0 
0 Obese 
 
Festi57 
 
Italy 16 16 
VLCD + high-fat;  
VLCD + low-fat 12 12* 
115 
110 
20 
19 
17 
17 
5 
5 Obese 
 
Gebhard67 
 
USA 7 6 
LCD + high-fat;  
VLCD + low-fat 12 12* 
114 
105 
25 
23 
22 
22 
0 
0 Obese 
 
Marks134 
 
USA 
16 
15 
16 
VLCD + 1200 mg UDCA;  
VLCD + 1600 mg ibuprofen; 
VLCD + placebo 
12 12 
100 
110 
114 
10$ 
11$ 
11$ 
10 
10 
10 
20§ Obese 
 
Mendez - 
Sanchez140 
 
Mexico 
14 
14 
14 
LCD + 1200 mg UDCA; 
LCD + 11.3 g omega-3 fatty acids; 
LCD + placebo 
6 6 
80 
84 
82 
6 
7 
6 
8 
8 
7 
4§ Obese 
 
Miller141  
 
Austria 76 76 
500 mg UDCA;  
placebo 24  96 
136 
136 
50 
51 
37 
38 
12 
16 
Obese  
(post bariatric surgery) 
 
Moran149 150 
 
Mexico 18 18 
LCD + 750 mg UDCA; 
LCD + 15g fibre 8 8 
90 
86 
6 
6 
7 
7 
0 
0 Obese 
 
Shiffman191  
 
USA 742 255 
VLCD + 300/600/1200 mg UDCA; 
VLCD + placebo 16 16 
128 
129 
25 
24 
20 
19 255
§
 
Obese 
 
Sugerman213 
 
USA 231 74 
300/600/1200 mg UDCA;  
placebo 24 24
†
 
137 
144 
40 
38 
29 
26 72
§
 
Obese  
(post bariatric surgery) 
 
Williams254  
 
Canada 44 42 
10 mg/kg UDCA; 
placebo Up to 72 Up to 72 - 
40 
43 - 
6 
0 
Obese 
 (post bariatric surgery) 
 
Worobetz256  
 
Canada 13 16 
1000 mg UDCA;  
placebo 12 12 
147 
143 
25 
29 
17 
20 
3 
2 
Obese  
(post bariatric surgery) 
 
Wudel257 
 
USA 
20 
20 
20 
600 mg UDCA;  
600 mg ibuprofen;  
placebo 
24 48 159 48 28 
5 
5 
9 
Obese 
(post bariatric surgery) 
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 39 
 
Abbreviations: LCD, low calorie diet; UDCA, ursodeoxycholic acid; VLCD, very low calorie diet 
*The entire study duration was 24 weeks, however only the first 12 weeks were included in this systematic review as this was the weight loss phase. 
†54 patients were followed up for 48 weeks but only data from the 24-week time point is included. 
$ Weight loss reported only for the six-week time point 
§Reported no significant difference between groups.  
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4.2 Risk of bias in included studies   
 
Overall the aggregate selection, performance and detection bias was relatively low in 
comparison to attrition, reporting and other biases, as illustrated in figure 3 below.   
 
 
 
 
 
 
    Figure 3.  Aggregate risk of bias for all included trials 
 
Specifically, none of the trials were classed as having a high risk of bias based on the 
allocation methods (see Figure 4). Two trials did not mention the allocation sequence 
generation, and two trials did not describe the allocation concealment. Two trials 
were classed as having a high or unclear risk of performance and detection bias. The 
remaining trials were double-blind and included blinding of outcome assessors as 
well as participants. Seven trials were classed as having a high risk of attrition bias 
because data on patients who were lost to follow up were incomplete. This was 
considered the main source of bias in these trials. For three trials134 191 213 the 
allocation group was not specified for participants with missing outcome data. Four 
trials did not report the clinically important outcomes at all the measured time points. 
These included one trial from the dietary fat modification interventions67 and three 
from the intervention trials with UDCA.35 134 254 In the other trials included in the meta-
analyses, outcomes measures were explicitly defined and reported.  
Four trials were funded by pharmaceutical companies either fully191 213 or partially.254 
257
 The industry funding did not obviously affect the overall trial design or analysis, as 
the dose and duration of the interventions assessed did not differ from remaining 
trials. Two trials were terminated early due to high attrition and slow recruitment134 or 
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because the incidence of symptomatic gallstones was considered too high in the 
control group.67 Five trials reported power calculations,67 141 149 191 213 and one of 
these trials did not achieve the expected power.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Figure 4.  Individual trial risk of bias for each domain 
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4.3 UDCA interventions 
 
As shown in Figure 5 below, from the 12 trials on UDCA versus control interventions, 
66 of 1,269 participants (5%) in the intervention group and 145 of 628 participants 
(23%) in the control group developed gallstones, which corresponds to a risk ratio of 
0.32 (0.19 to 0.55, I²=60%). The corresponding NNT was 13 patients. No deaths 
were reported.  
 
 
 
 
 
 
 
Figure 5.  Meta-analysis of gallstone formation in patients receiving UDCA versus control 
interventions 
 
Six trials reported the number of participants who underwent cholecystectomy due to 
symptomatic gallstones.5 35 141 213 256 257 Two of these trials however, did not report 
the allocation group for these participants.35 257 A meta-analysis of the weight loss 
trials showed that UDCA reduced the risk of cholecystectomy for symptomatic 
stones, with a risk ratio of 0.19 (0.07 to 0.49, I²=0%, Figure 6). 
 
 
 
 
Figure 6.  Meta-analysis of cholecystectomy in obese patients receiving UDCA versus 
control interventions during weight loss 
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Due to differences in the assessment of bile lithogenicity, we were unable to perform 
meta-analyses on this physical-chemical outcome. Two35 134 of three diet alone trials 
found a significantly beneficial effect of UDCA versus placebo on CSI and the third 
trial reported a decreased trend for the UDCA group and an increased trend for the 
placebo group.191 A fourth trial noted that the CSI did not significantly change during 
the trial in any of the groups, though a decreased trend was observed and 
cholesterol nucleation time decreased significantly in both UDCA and placebo 
groups.140 Finally, one trial35 also reported a significant increase in CSI at week four 
(from baseline) in those who developed gallstones and was significantly higher than 
those who did not develop gallstones (who had no significant change from baseline).  
Weight loss was equal in the UDCA and placebo groups in all trials (range 6 - 51 kg). 
35
 
47
 
134
 
140
 
141
 
149
 
191
 
213
 
254
 
256
 
257
 We were able to include data from four trials in the 
meta-analysis below (Figure 7), confirming the finding of equal weight loss, with a 
weighted mean difference of -0.01 (-1.07 to 1.06, I2=0%).35 140 149 191 
 
 
 
 
 
 
 
Figure 7.  Meta-analysis of weight loss in obese patients receiving UDCA versus control 
interventions during weight loss 
 
4.3.1 Subgroup and sensitivity analyses 
 
Amongst the weight loss trials, Figure 8 illustrates that UDCA was more beneficial 
when only caloric restriction was used for weight loss as compared to the trials that 
also included bariatric surgery (P=0.03). This finding was corroborated when using 
an available case analysis (test for subgroup differences P=0.02). 
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Figure 8.  Meta-analyses of gallstone formation in obese patients receiving UDCA versus 
control interventions during weight loss with diet alone or after bariatric surgery based on ITT 
(top) and per protocol (bottom) analysis 
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The effect of UDCA did not differ between trials on weight loss or cardiac surgery 
(test for subgroup differences P=0.76) (see Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Meta-analysis of gallstone formation in patients receiving UDCA versus control 
interventions based on patient type (i.e. obese patients during weight loss versus non-obese 
patients post cardiac surgery) 
 
The type of bariatric surgery (Figure 10, top) did not influence the effect of UDCA 
(test for subgroup differences P=0.92). Likewise, no difference was seen between 
trials which administered the lower or higher dose of UDCA (test for subgroup 
differences P=0.12) (see Figure 10, bottom). 
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Figure 10.  Meta-analyses of gallstone formation in patients receiving UDCA versus control 
interventions based on type of bariatric surgery (top) and dose of UDCA (bottom) 
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There were no available data to assess quality of life. There was no difference 
between trials with a low compared to a high or unclear risk of bias based on the 
allocation or blinding methods (test for subgroup differences P=0.76 for both 
analyses), or in subgroups of trials stratified by attrition bias (test for subgroup 
differences P=0.54), reporting of outcomes (test for subgroup differences P=0.80), or 
other biases (test for subgroup differences P=0.65). The effect of UDCA was 
confirmed when the analyses were repeated using good or poor outcome analysis 
(P=0.00002 and P<0.00001, respectively). All the figures for the above bias analyses 
can be found in appendix 5. 
 
4.3.1 Regression and trial sequential analyses 
 
No evidence of small study effects was identified (Egger's test P=0.53) as illustrated 
in the funnel plot below (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Funnel plot of trials using UDCA versus control interventions 
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A sequential analysis was performed using relative risks (random effects) and with 
alpha set to 5% and power to 80%. The relative risk reduction was set to 77%, the 
incidence in the control group to 20% and the heterogeneity to 80%. The graph 
(Figure 12) did not confirm the overall result of the meta-analysis, since the trial 
sequential monitoring boundary (inward sloping red line) was not crossed before 
reaching the required information size.  
 
 
 
 
 
 
 
 
 
 
Figure 12.  Trial sequential analysis of UDCA versus control interventions in all trials 
The required information size was calculated to 432 participants based upon a control group 
gallstone incidence of 23%; a relative risk reduction of 77%; an alpha of 5%; a beta of 20% 
(80% power). The blue cumulative Z curve crosses the conventional alpha of P = 0.05, but 
does not touch the trial sequential alpha spending monitoring boundaries (inward sloping red 
lines). 
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We also repeated the regression and sequential analyses for trials on weight loss 
through diet alone or post bariatric surgery. No small study effects were seen when 
analysing trials on diet alone (Egger's test P=0.284) or trials on bariatric surgery 
(P=0.989). The sequential analyses did confirm the results of the subgroup 
analyses of trials on weight loss through diet alone as it crossed the sequential 
monitoring boundary (Figure 13) but sequential analysis did not confirm the results 
of the meta-analysis for the trials that included participants post bariatric surgery 
(Figure 14).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Trial sequential analysis of UDCA versus control interventions on diet alone 
The required information size was calculated to 128 participants based upon a control group 
gallstone incidence of 19%; a relative risk reduction of 82%; an alpha of 5%; and a beta of 
20% (80% power). The blue cumulative Z curve crosses the conventional alpha of P=0.05 
twice, and the trial sequential alpha spending monitoring boundaries (inward sloping red 
lines). 
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Figure 14.  Trial sequential analysis of UDCA versus control interventions post bariatric 
surgery 
The required information size was calculated to 389 participants based upon a control group 
gallstone incidence of 29%; a relative risk reduction of 68%; an alpha of 5%; and a beta of 
20% (80% power). The blue cumulative Z curve crosses the conventional alpha of P=0.05, 
but not the trial sequential alpha spending monitoring boundaries (inward sloping red lines). 
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4.4 Interventions with dietary fat modification 
 
The non-pharmacological interventions assessed included high versus low-fat diets 
during weight loss (two trials). The weight loss in the intervention and control groups 
ranged from 19 to 25 kg.57 67 None of the 23 participants in the intervention group and 
10 of 22 (45%) participants in the control groups developed gallbladder stones. 
Random effects meta-analysis (Figure 15) showed that high dietary fat modification 
during weight loss reduced the risk of gallstones (risk ratio, 0.09, 0.01 to 0.61, 
I²=0%). No deaths were reported. Quality of life was not assessed. Both trials 
reported a similar pattern in bile lithogenicity in both treatment groups, but did not 
report data that allowed meta-analyses. The trials described an initial increase in 
lithogenicity following the diet and subsequently a decrease to values lower than 
those at baseline during follow-up. We were unable to analyse the outcomes 
cholecystectomy or weight loss due to differing reporting methods.  
 
 
 
 
 
Figure 15.  Meta-analysis of gallstone formation in patients receiving a high-fat versus a low-
fat weight loss diet 
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4.5 Other pharmacological/non-pharmacological interventions 
 
The number of trials and participants assessing aspirin, ibuprofen and omega-3 fatty 
acids was small (Figure 16). One trial257 found that patients receiving ibuprofen 
formed gallstones at a higher rate than the placebo or UDCA groups. This was a trial 
with high attrition. Adverse events were not clearly reported. None of the remaining 
interventions demonstrated beneficial or detrimental effects on gallstones. These 
results and those of the subgroup analyses above are presented in table 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Meta-analyses of gallstone formation in patients receiving various interventions 
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Table 5.  Summary of subgroup random effects meta-analyses 
 
Abbreviations: NA, not applicable; NE, not estimable 
Outcome or Subgroup Studies N Effect Estimate                                      
RR [95% CI] 
Heterogeneity
I2 % 
Gallstone formation in trials on diet alone or bariatric 
surgery using available case analysis 
11 1470 0.34 [0.19, 0.59] 66 
   Weight loss diet alone 6 949 0.17 [0.11, 0.26] 0 
   Bariatric surgery 5 521 0.40 [0.22, 0.74] 59 
Gallstone formation in different types of bariatric surgery 5 612 0.42 [0.21, 0.83] 64 
   Gastric bypass 2 345 0.45 [0.10, 2.06] 87 
   Gastroplasty/gastric banding 3 267 0.42 [0.19, 0.91] 38 
Gallstone formation in relation to dose of UDCA 10 1728 0.21 [0.10, 0.42] 66 
   UDCA 500-750 mg 6 930 0.29 [0.11, 0.75] 73 
   UDCA 1000-1200 mg 6 798 0.11 [0.06, 0.22] 0 
Gallstone formation in relation to allocation methods 12 1897 0.32 [0.19, 0.55] 60 
   Low risk of bias 11 1791 0.33 [0.18, 0.60] 65 
   Unclear risk of bias 1 106 0.28 [0.10, 0.78] NA 
Gallstone formation in relation to blinding 12 1897 0.32 [0.19, 0.55] 60 
   Low risk of bias 11 1791 0.33 [0.18, 0.60] 65 
   High risk of bias 1 106 0.28 [0.10, 0.78] NA 
Gallstone formation in relation to attrition bias 12 1897 0.32 [0.19, 0.55] 60 
   Low risk of bias 5 562 0.26 [0.16, 0.42] 0 
   High risk of bias 7 1335 0.36 [0.14, 0.90] 81 
Gallstone formation in relation to selective reporting 12 1897 0.32 [0.19, 0.55] 60 
   Low risk of bias 9 1733 0.30 [0.17, 0.51] 57 
   High risk of bias 3 164 0.38 [0.06, 2.61] 51 
Gallstone formation in relation to other bias 12 1897 0.32 [0.19, 0.55] 60 
   Low risk of bias 5 291 0.28 [0.14, 0.57] 0 
   High or unclear risk of bias 7 1606 0.36 [0.18, 0.72] 76 
Gallstone formation good outcome analysis 11 1791 0.39 [0.25, 0.60] 37 
Gallstone formation poor outcome analysis 11 1791 0.59 [0.51, 0.68] 0 
Aspirin versus placebo 1 45 0.42 [0.09, 1.94] NA 
Aspirin versus UDCA 1 45 5.22 [0.26, 102.93] NA 
Ibuprofen versus placebo 2 71 2.00 [1.03, 3.88] NA 
Ibuprofen versus UDCA 2 71 2.00 [1.03, 3.88] NA 
Omega 3 fatty acids versus placebo 1 28 NE NA 
Omega 3 fatty acids versus UDCA 1 28 NE NA 
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4.6 Adverse events 
 
UDCA did not increase the risk of adverse events (Table 6). Overall, few serious 
events were reported. The most common adverse events were gastrointestinal-
related complaints. Only one185 of the three138 146 185 trials included qualitatively in 
this review reported adverse events with UDCA supplementation. No adverse events 
were described in the dietary fat modification trials.  
Table 6.  Reported adverse events with UDCA administration 
Trial  UDCA mg 
(per day) 
No. adverse   
events in 
treatment  
group % (n) 
Type of adverse events  
in treatment group  
(n or %) 
Type of adverse events  
in control group 
(n or %) 
Ai5 600  
Did not report 
on adverse 
events at all 
- - 
 
Broomfield35 
 
1200  
Did not report 
on adverse 
events at all 
- - 
 
De Filippo47 
 
600  0 - - 
 
Marks134 
 
1200  0 - - 
Mendez-
Sanchez140 1200  13 (2) 
Abdominal bloating and 
constipation (n=2) 
Abdominal bloating and 
constipation (n=2) † 
Miller141 500  8 (6) Nausea, constipation (n=6)* Nausea, constipation (n=2)* 
 
Moran149 150  
 
750  0 - - 
Scott185  600  25 (17) 
Nausea (n=9) 
Diarrhoea (n=5) 
Dry skin/pruritus (n=3) 
Not reported 
 
Shiffman191  
 
300/600/1200  Not reported 
Common complaints were*:  
Constipation (27%) 
Headache (27%) 
Diarrhoea (23%) 
Dizziness (17%) 
Upper respiratory infections (16%) 
13 patients withdrew due to 
adverse events 
Common complaints were*:  
Constipation (26%) 
Headache (30%) 
Diarrhoea (24%) 
Dizziness (16%) 
Upper respiratory infections 
(13%) 
5 patients withdrew due to 
adverse events 
 
Sugerman213  
 
300/600/1200  Not reported Vomiting or skin rashes* Vomiting or skin rashes* 
 
Williams254  
 
10 (mg/kg)  9 (20)  
 
Medication intolerance (n=9)* Medication intolerance (n=7)* 
 
Worobetz256  
 
1000  8 (1) 
Epigastric burning upon 
medication ingestion and was 
withdrawn (n=1) 
 
 
Wudel257 600  
Did not report 
on adverse 
events at all 
- - 
 
*no differences in adverse events between the placebo and intervention groups. 
†These adverse events were reported for the group receiving omega-3 fatty acids. 
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5. Discussion 
5.1 Summary of main results  
 
This systematic review suggests that UDCA and high-fat weight loss diets may be 
considered in the primary prevention of gallstones during weight loss. Our meta-
analyses mainly include obese adults, who belong to a high risk group with regards to 
cholesterol gallstone formation. No effect on mortality was established and no major 
adverse effects were reported. The effects on bile lithogenicity could not be meta-
analysed, but some trials found improvements with UDCA administration. This is 
consistent with the reduced cholesterol supersaturation of bile, the physical-chemical 
prerequisite for lowering gallstone risk.  
 
5.1.1 Efficacy of UDCA for gallstone prevention  
 
The number of patients who developed gallstones in the UDCA and control groups 
was 5 versus 23%, respectively. Of note, none of the trials reported significant 
differences in weight loss between the intervention and the control groups. The NNT 
to prevent one patient from forming gallbladder stones will depend on the baseline 
weight of the included patients. Our results suggest that about 13 patients have to be 
treated with UDCA to prevent one patient from developing gallstones. We have no 
data to allow an assessment of the NNT to prevent one patient from developing 
symptomatic stones, but the expected incidence suggests that the number will be 
considerably higher.  
The one trial comprising patients post cardiac surgery found a reduced incidence of 
gallstones in those receiving UDCA compared to controls. Incidentally, most of the 
gallstones in the controls were black pigment stones. The relevance of this outcome 
with UDCA is exemplified by the recently published study investigating outcomes of 
cholecystectomy in 1,687 US heart transplant recipients.100 Mortality in this cohort 
was 2.2% and predictors included open cholecystectomy and gallstone disease. The 
authors urge that consideration should be given before prophylactic cholecystectomy 
is performed.  
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The observed effect in our meta-analysis on obese subjects undergoing weight loss 
seemed to depend on the weight loss method, with patients on bariatric surgery 
having a smaller benefit than patients on diets alone. Gallstone incidence in the 
UDCA and control groups was 3 and 19% (diet alone trials), compared to 9 and 28% 
(post bariatric surgery trials). Our data do not allow an assessment of the reason for 
the difference, however, a weight loss greater than 25% body weight is reported to 
increase the risk of gallstones forming.127 However, the influence of absolute weight 
loss on gallstones has yielded conflicting findings, as several prospective 
observational studies in morbidly obese participants presenting for bariatric surgery 
have not observed a linear relationship between body weight and the prevalence of 
gallstones, and absolute amount of weight loss presented no increased risk in these 
participants.189 190 Despite these findings, a curvilinear relationship between the rate 
of weight loss in obese participants and the incidence of gallstones has indeed been 
demonstrated,251 with a maximum of 1.5 kg per week being assessed as optimal to 
limit the risk.  
Moreover, differences in intestinal and/or gallbladder motility as well as baseline 
patient characteristics may have contributed to these findings. A non-randomised trial 
excluded from this review found rapid weight loss post laparoscopic gastric banding 
to impair gallbladder emptying.7 Parenteral nutrition studies highlight the role of 
gallbladder hypomotility in the development of gallstones, which can prolong the 
residence time of excess cholesterol in the gallbladder and promote biliary sludge 
formation.195 Gallbladder motility may be modulated by a high-fat diet and UDCA in 
different ways,99 190 with some of the included trials that assessed gallbladder 
function reporting reduced gallbladder contraction in the placebo compared to the 
UDCA groups,35 134 or significantly faster gallbladder emptying after a three-month 
intervention with UDCA compared to placebo.257  
 
5.1.2 When to initiate UDCA therapy 
 
An important consideration is when to begin prophylactic UDCA therapy. Non-
surgical trials commenced UDCA therapy immediately upon caloric restriction, 
whereas bariatric surgery trials initiated UDCA within days,141 213 256 or weeks of 
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surgery.254 Since gallstones take approximately four weeks to develop, preventive 
treatment should theoretically begin immediately. Observational studies189 190 report 
the incidence of ultrasonically verified gallstones to approximate 36% within six 
months after Roux-en-Y gastric bypass, and the incidence of gallstones stabilises 
from thereon, when assessed at 12 and 18 months. Most of the UDCA interventions 
included in these meta-analyses lasted between three and six months, coinciding 
with when the majority of weight loss occurs. This could indicate a 'critical period' for 
initiating interventions to prevent gallstones in these patients.  
 
5.1.3 Effect of low-calorie diets on gallstones  
The risk of gallstones appears to be significant in both LCD and VLCDs.201 258 259  
Most recently, a study of 8,361 individuals reported the risk of symptomatic 
gallstones including cholecystectomy to be three times higher in those treated with a 
VLCD as compared to a LCD.90 This study did not assess the presence of gallstones 
at baseline with ultrasonography. One would expect however, that VLCDs as 
compared to LCDs further increase the risk of gallstones, particularly as weight loss 
is more rapid with the former. The authors speculate that the dietary fat content 
(which was between 7 g and 9 g) might have played an influential role.90 This was not 
as low as that of the low-fat diets in the trials included in this meta-analysis (1 - 3 g), 
but it was also not as high as that of the high-fat diets (12 - 30 g) of the trials herein.  
 
5.1.4 Influence of dietary fat content on gallstones 
We compared the rate of gallstone formation in the placebo groups of the trials that 
provided participants with a VLCD (~500 kcal) and between 1 g to 3 g fat. The 
incidence of gallstones ranged from 0% to 66.7%, with a median of 22.3%.35 57 67 134  
191
 In this review, a weight reducing diet higher in fat (19 - 30%) appears to reduce 
the incidence of gallstones compared to a weight reducing diet lower in fat (3 - 5%). 
No adverse events were reported, but the trials were not free from bias; our analysis 
only included two trials with small sample sizes. Although this finding must be 
interpreted with caution, a mechanistic rationale exists, since a diet higher in fat 
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stimulates gallbladder contractility.67 210 Conversely, a low-fat diet is associated with 
gallbladder stasis and may increase the risk of gallstones – a finding that has also 
been reported in other non-randomised studies using VLCD and 1 g fat, not included 
in this systematic review.128 258  
Both the studies included in the meta-analysis reported greater gallbladder emptying 
when subjects received a high fat test meal compared to a low fat test meal. 
Specifically, Gebhard et al.67 compared two liquid diets with different caloric and fat 
contents (520 kcal + < 2 g fat versus 900 kcal + 30 g fat distributed between three 
meals). Gallbladder emptying was compared between the low-fat meal (< 2 g) versus 
the high-fat (10 g) meals, and poor gallbladder emptying was reported with the 
former. Festi et al.57 compared two isocaloric VLCD with different fat content (3 g 
versus 12.2 g/day) and found gallbladder emptying was significantly lower in the low-
fat diet group. Finally, these two studies also noted a similar pattern in CSI in both 
treatment groups. This included an initial increase in CSI after six57 and eight 
weeks,67 followed by a decrease to values lower than those at baseline after three57 
and six months.67 This is synonymous with reports of increased cholesterol 
mobilisation during weight loss, which gradually tapers off. Correspondingly, the 
incidence of gallstones was higher in the low-fat diet groups in both studies.  
 
5.2 Possibility of new prevention modalities 
Given the findings of these meta-analyses, there may even be the potential to 
ameliorate gallstone risk in patients with a combination of non-pharmacological and 
pharmacological means, whereby a weight reducing diet with a relatively high fat 
content is provided alongside UDCA therapy. The higher risk of gallstones during 
weight loss indicates reduced gallbladder motility due to reduced gallbladder 
stimulation and the presence of increased bile lithogenicity, most likely due to 
increased reverse cholesterol transport and reduced biliary bile salt secretion.24 71 
Interestingly, the pathogenesis of cholesterol gallstones suggests that the lithogenic 
state may be irreversible as a result of cholesterol absorption by the gallbladder wall 
with subsequent disruption of smooth muscle function.119 Research on gallstone 
incidence and on cholesterol and fat intake is controversial and may depend on lipid 
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composition. For example, an increased gallstone incidence was reported with a 
higher saturated and trans fat intake in some prospective follow-up studies,225 231 but 
reduced with a high polyunsaturated and monounsaturated fat intake.222  
 
5.3 Consideration of non-modifiable risk factors  
Non-modifiable risk factors, such as genetics, should also be taken into account 
because they are reported to account for about 25% of gallstone risk.95 In particular, 
mutations in genes encoding hepatocanalicular transporters are reported to cause 
cholelithogenesis given their aptitude in modifying bile composition and causing 
retention of substances normally secreted in bile, thus influencing the bile formation 
process. The influence of the ABCG5/G8 gene variants (two cholesterol hemi-
transporters) on intestinal absorption and biliary secretion of cholesterol may play a 
significant role.25 In fact, they function together as a heterodimer influencing 
cholesterol excretion so intensely, that related loss-of-function mutations are shown 
to cause sitosterolemia (a rare genetic disorder of lipid metabolism, characterized by 
excess concentrations of cholesterol and phytosterols) in serum).59  
Moreover, the ABCG8 mutation p.D19H variant has been identified in independent 
cohorts worldwide as a common susceptibility factor for cholesterol gallstone 
disease.36 69 ABC transporters control biliary lipid secretions across the canalicular 
hepatocyte membranes and therefore play a crucial role in regulating the physical-
chemistry of bile. Given the inherent predisposition to gallstones, genetic screening 
for high risk individuals might help in the precise identification of candidates for 
primary stone prevention with UDCA and/or high-fat diets, drugs inhibiting cholesterol 
synthesis and/or intestinal absorption, or modulators of nuclear receptors involved in 
cholesterol and bile acid homeostasis.12 41 109 However, RCTs would need to be 
conducted before this approach can be fully endorsed. Figure 17 depicts the 
sequence of considerations that could be followed for the prevention of gallstones in 
obese patients wishing to lose weight.  
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Figure 17. Flow chart for preventive options against gallstones during weight loss 
Abbreviations: ABCB4, ATP-binding cassette transporter, subfamily B, member 4; ABCB11, 
ATP-binding cassette transporter, subfamily B, member 11; ABCG5, ATP-binding cassette 
transporter, subfamily G, member 5; ABCG8, ATP-binding cassette transporter, subfamily G, 
member 8; GL, glycaemic index; LCD, low-calorie diet; UDCA, ursodeoxycholic acid; VLDC, 
very low-calorie diet 
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5.4 Summary of secondary findings  
 
5.4.1 Acetylsalicylic acid in patients following a VLCD 
 
Only one study assessed acetylsalicyclic acid (aspirin) against UDCA therapy or 
placebo for gallstone prevention. Broomfield et al.35 included obese patients 
undergoing weight loss only by using a VLCD (i.e. without bariatric surgery). After 16 
weeks of treatment, they observed the highest incidence of gallstones to occur in 
patients in the placebo group, followed by those in the aspirin group and no 
gallstones were found in the UDCA group. This is suggestive, yet inconclusive of a 
beneficial effect of aspirin on gallstone prevention.   
 
The evidence surrounding the role of aspirin in gallstone prevention is relatively 
scarce. Because aspirin is a prostaglandin inhibitor, its beneficial mechanistic effects 
are believed to result from the inhibition of mucin glycoprotein secretion in the 
gallbladder.77 Such a finding was reported in prairie dogs by LaMont and coworkers, 
121
 whereby oral aspirin intake prevented cholesterol gallstones formation. 
Interestingly, in the trial by Broomfield et al.35 increased glycoprotein concentrations 
in bile were observed in patients in the placebo group (regardless of whether they 
formed gallstones or not), but not in the non-stone formers of the UDCA or the aspirin 
group. However, in the two patients in the aspirin group who formed gallstones (and 
also in one patient who had crystals), there was an increased glycoprotein 
concentration, as compared to the non-stone formers. Moreover, Broomfield et al.35 
also noted decreased prostaglandin concentrations in the group receiving aspirin, 
whereas both the UDCA and the placebo groups displayed increased concentrations. 
One limitation to the above findings in this study is that only two patients in the aspirin 
group formed gallstones, and both these patients had very low concentrations of 
aspirin in serum, which is suggestive of non-compliance with the study regime.  
 
A lack of a protective effect of aspirin was subsequently reported by Kurata et al.111 
who assessed whether aspirin taken orally reduced the need for gallstones-related 
hospitalization, rather than for prophylaxis against gallstones per se. This study 
included 4,524 subjects from the AMIS study (The Aspirin Myocardial Infarction 
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Study) of whom 2,267 were randomized to receive 500 mg aspirin twice daily and 
2,257 placebo. All subjects were followed up for three years. No baseline differences 
were detected between the two groups. The follow-up revealed that only 11 patients 
were hospitalised for gallstones during this time period but that aspirin did not 
necessarily reduce hospitalisation for gallbladder disease.  
 
 
5.4.2 Ibuprofen in patients following a VLCD 
 
Two of the included trials assessed ibuprofen for the prevention of gallstones during 
weight loss and the findings are inconclusive with regard the efficacy of ibuprofen for 
gallstone prevention during weight loss. In one of the trials,134 obese patients 
followed a VLCD for 12 weeks and received either 12 mg UDCA or 1600 mg 
ibuprofen or a placebo daily. None of the patients in this study developed gallstones. 
In the second trial,257 obese patients received 600 mg UDCA or 600 mg ibuprofen or 
placebo daily for 24 weeks post bariatric surgery. In each of the UDCA and placebo 
groups 7/20 patients developed gallstones compared to 14/20 patients in the 
ibuprofen group respectively. This study however, was biased because of an 
excessively high attrition rate. In fact, a per protocol analysis (including only the 
patients who finished the study) showed gallstones developed in 7/15 and 7/11 
patients in the UDCA and placebo groups, respectively. In the ibuprofen group, 14/15 
patients formed gallstones. Therefore incidence of gallstones was lowest in the 
UDCA group but surprisingly was highest in the ibuprofen group. Further analyses in 
this study noted a higher percentage of gallbladder emptying in the UDCA group 
three months post surgery; this was reduced in comparison in the ibuprofen group.  
One reason for this unexpected finding could be that stone formers in this study lost 
more weight compared to the non-stone formers and that many of these patients 
happened to be allocated to the ibuprofen group. In addition, not only was attrition 
high in this study, but compliance was assessed with self report measures via 
telephone interviews. Complete compliance was achieved in only 28% of patients. 
The authors report no differences in self report assessment of compliance between 
groups or between stone and non-stone formers, but there may generally have been 
bias in the self recall process.  
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There is a clear discrepancy in stone formation in those taking ibuprofen between the 
two trails mentioned above. This difference may be attributable to the dosage given, 
i.e. 1600 mg in the group in which no stones were observed134 versus 600 mg in the 
group in which most subjects formed stones.257 This could provide indications on 
what could theoretically be deemed an adequate therapeutic dose. More trials 
however, would be needed to substantiate this. Moreover, ibuprofen should reduce 
the risk of stone formation via prostaglandin inhibition and reduction of nucleation 
and growth of cholesterol crystals, as reported with aspirin.204 One could hypothesise 
that the observed increased risk of gallstones with ibuprofen may be related to the 
fact that these patients had undergone bariatric surgery, compared to the other trial in 
which only a VLCD as a weight loss method was used. However, another trial studied 
the influence of long term use of non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. 
< two months) in 230 morbidly obese patients immediately post gastric bypass and 
found NSAID use to be associated with reduced mucin concentrations and lower 
cholesterol/phospholipid ratios in gallbladder bile.204 The increased risk may therefore 
be attributable to confounding factors not controlled or clearly accounted for in this 
one trial.257  
 
5.4.3 Omega-3 fatty acids in patients following a LCD 
 
Only one trial investigated the effects of omega-3 fatty acid for prevention of 
gallbladder stones during weight loss and did not observe any incidence of gallstones 
in 15 obese women when taking 11.3 g/day of omega-3 fatty acids.140 Likewise none 
of the participants in the placebo group or those receiving UDCA developed 
gallstones. However, all participants followed a LCD as co-intervention and the entire 
study duration was six weeks, therefore this may not have been long enough to see 
an effect since the weight loss would not be as rapid with a LCD.  
A low prevalence of cholesterol gallstones has been reported in populations 
consuming omega-3 fatty acids (such as in Alaskan natives),32 however this may be 
attributable to synergistic effects of the non-Westernised diet (i.e. low in refined 
carbohydrates) being consumed. Nevertheless, a study in patients with existing 
gallstone disease reported a decrease in biliary cholesterol saturation, following 
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intake of 3.75 g omega-3 fatty acids daily.26 The above study included in this review 
also assessed CSI and did not find a difference between any of the groups during the 
intervention duration. Cholesterol nucleation time decreased in the placebo and in 
the UDCA group but did not change in the omega-3 fatty acid group. Since this 
finding is unexpected for the UDCA group, the authors speculate that this might be 
due to the short intervention duration.  
In addition, experimental studies studied dietary fish oil supplementation in African 
green monkeys and found a reduced gallstone incidence and a lower CSI in those 
fed a diet with fish oil (22%) compared with 67% in those fed a diet with lard.184 More 
recently, omega-3 fatty acids are reported to attenuate cholesterol gallstones in mice 
through suppressing mucin production.101 In summary, further research, particularly 
in the form of clinical trials is warranted to evaluate whether omega-3 fatty acids 
could play a role in gallstone prevention.  
 
5.5 Strength and limitations of the findings 
 
This is the first review on several non-surgical interventions for the prevention of 
gallstones. UDCA reduced the risk of gallstones compared with control interventions 
and was more beneficial in participants undergoing weight loss through diet alone 
than after bariatric surgery. A high-fat low calorie diet also reduced the formation of 
gallstones during weight loss. We were unable to comment on the development of 
symptomatic gallstones in all included trials but a recent meta-analysis of 6,048 
obese patients concluded that prophylactic cholecystectomy during laparoscopic 
gastric bypass should be avoided in patients without gallstones due to the low 
necessity of subsequent cholecystectomy (< 6.8%).248 These findings may have 
important implications as the question of whether to perform cholecystectomy to 
prevent gallstones, particularly in obese patients undergoing weight loss, is 
debatable. A cost-effectiveness study of prophylactic cholecystectomy stated that the 
primary factor influencing the cost-effectiveness model is the incidence of 
gallbladder-related symptoms post-surgery.23 A review of the evidence in 2010 
reported a relatively low incidence of gallstones (5 - 10%) post gastric bypass in 
patients who did not take UDCA and that the majority of gallstone cases were 
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asymptomatic.173 A similar finding was reported in a study comprising 13,443 
participants post bariatric surgery who were followed up for 22 years.169 Although the 
postoperative rate of obese participants requiring cholecystectomy is higher than the 
general population, the actual risk remains low. Hence, a conventional approach (i.e. 
using non-surgical means for primary stone prevention) may be preferred.  
The small number of identified trials and correspondingly low sample sizes for some 
of the meta-analyses is the main limitation of this review, particularly for the non-
pharmacological interventions. Several clinically relevant outcomes were also not 
addressed in the identified trials, in particular quality of life measures. Moreover, a 
high risk of attrition bias was identified as several trials reported high drop-out rates, 
and this was reflected in the meta-analyses. The complexity with these trials is that 
participants were following a weight loss diet (as co-intervention) which, by default, 
yields high attrition.78 It is possible that the poor compliance reflects the difficulty in 
following the weight loss diets, rather than with the interventions for primary stone 
prevention. In support of this, many trials did not find significant differences in attrition 
or in adverse events between the treatment and control groups.  
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6. Conclusions and clinical implications 
 
The obesity epidemic in both adults and children contributes to the increased 
prevalence of gallstones. Given that obese adults and children are also attempting to 
lose weight, we may consequently be faced with an ever-growing incidence of 
gallstones, thereby further compounding the current burden on the healthcare 
system. Though mortality is rare in cholelithiasis, morbidity is high. Therefore, early 
intervention is crucial, particularly as it has been documented as an adverse event in 
those undergoing rapid weight loss. Non-surgical options for the prevention of 
gallstones currently remain underused in clinical practice. The meta-analyses herein 
suggest that UDCA and a diet higher in dietary fat may prevent gallbladder stones 
forming during weight loss. We need to call more attention to the potential benefits of 
therapies such as the specific nutritional composition of weight loss diets and/or 
UDCA. Evidence-based guidelines are needed to identify interventions that could be 
feasible to use in practice, particularly in individuals at highest (genetic) risk. Further 
research encompassing genetic screening in obese patients undergoing weight loss 
would also help elucidate whether the risk of gallstones can be genetically quantified 
in such patients, risk of stones accurately predicted and subsequently avoided with 
the aforementioned interventions. Furthermore, responsible dietary advice for obese 
patients is paramount regardless of whether weight loss is attempted through lifestyle 
changes or bariatric surgery.  
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_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 102
9. 7 or 8 
10. exp Obesity/ 
11. obesity.mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
12. 10 or 11 
13. exp Bariatric Surgery/ 
14. bariatric surger*.mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
15. 13 or 14 
16. exp Weight Loss/ 
17. weight loss*.mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
18. 16 or 17 
19. exp Diet Therapy/ 
20. (diet therap* or caloric restriction or low calorie diet* or liquid diet* or fat* or 
protein* or carbohydrate* or fibre).mp. [mp=protocol supplementary concept, 
rare disease supplementary concept, title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
21. 19 or 20 
22. exp Micronutrients/ 
23. micronutrient*.mp. [mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
24. 22 or 23 
25. exp Exercise/ 
26. (physical activit* or exercise*).mp. [mp=protocol supplementary concept, 
rare disease supplementary concept, title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
27. 25 or 26 
28. 3 or 6 or 9 or 12 or 15 or 18 or 21 or 24 or 27 
29. exp Cholelithiasis/ 
30. (cholelithiasis or gallstone* or gall* stone* or 'black pigment stone*').mp. 
[mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
31. 29 or 30 
32. 28 and 31 
33. (random* or blind* or placebo* or meta-analysis).mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, original title, 
abstract, name of substance word, subject heading word, unique identifier] 
34. 32 and 33 
 
EMBASE (Ovid SP) 1980 to 
July  
2013 
1. exp echography/ 
2. (ultrasonograph* or ultrasound* or ecograph*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer] 
3. 1 or 2 
4. exp ursodeoxycholic acid/ 
5. (ursodeoxycholic acid* or ursodiol or UDCA).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer] 
6. 4 or 5 
7. exp nonsteroid antiinflammatory agent/ 
8. ((non-steroid* anti-inflammatory and (drug* or agent*)) or ibuprofen or 
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10. exp OBESITY/ 
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12. 10 or 11 
13. exp bariatric surgery/ 
14. bariatric surger*.mp. [mp=title, abstract, subject headings, heading word, 
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22. exp trace element/ 
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26. (physical activit* or exercise*).mp. [mp=title, abstract, subject headings, 
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manufacturer] 
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28. 3 or 6 or 9 or 12 or 15 or 18 or 21 or 24 or 27 
29. exp CHOLELITHIASIS/ 
30. (cholelithiasis or gallstone* or gall* stone* or 'black pigment stone*').mp. 
[mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer] 
31. 29 or 30 
32. 28 and 31 
33. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device 
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34. 32 and 33 
 
Science Citation Index 
Expanded 
1970 to 
July  
2013 
# 4 #3 AND #2 AND #1 
# 3 TS=(random* or blind* or placebo* or meta-analysis) 
# 2 TS=(cholelithiasis OR gallstone* OR gall* stone* OR black pigment stone*) 
# 1 TS=(ultrasonograph* OR ultrasound* OR ecograph* OR ursodeoxycholic 
acid* OR ursodiol OR UDCA OR (non-steroid* anti-inflammatory AND (drug* 
OR agent*)) OR ibuprofen OR aspirin OR obesity OR bariatric surger* OR 
weight loss OR diet therap* OR caloric restriction OR low calorie diet* OR liquid 
diet* OR fat* OR protein* OR carbohydrate* OR fibre OR micronutrient* OR 
physical activit* OR exercise*) 
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Appendix 2. Data collection form (template)  
 
Data	collection	form	
Intervention review – RCTs and non-RCTs 
 
Notes on using a data extraction form:  
• Be consistent in the order and style you use to describe the information for each report. 
• Record any missing information as unclear or not described, to make it clear that the information was not 
found in the study report(s), not that you forgot to extract it.  
• Include any instructions and decision rules on the data collection form, or in an accompanying document. 
It is important to practice using the form and give training to any other authors using the form. 
 
Review title or ID 
      
 
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)  
      
 
Report ID (if different to Study ID) Report IDs of other reports of this study (e.g. duplicate publications, follow-up 
studies) 
            
 
Notes:         
 
 
General Information 
 
Date form completed 
(dd/mm/yyyy)       
Name/ID of person extracting 
data 
      
 
Reference citation 
 
      
 
 
Study author contact details 
      
 
Publication type 
(e.g. full report, abstract, letter)       
 
Notes:       
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Study eligibility 
 
Study 
Characteristics 
Eligibility criteria 
(Insert inclusion criteria for each characteristic as 
defined in the Protocol) 
Eligibility criteria 
met?  
Location in text 
or source (pg & 
¶/fig/table/other) 
Yes No Unclear 
Type of study Randomised Controlled Trial 
   
      
Quasi-randomised Controlled Trial 
 
   
      
Controlled Before and After Study 
• Contemporaneous data collection 
• Comparable control site 
• At least 2 x intervention and 2 x control 
clusters 
   
      
Interrupted Time Series 
• At least 3 time points before and 
3 after the intervention 
• Clearly defined intervention point 
   
      
Other design (specify): 
      
 
   
      
Participants 
 
      
 
 
   
      
Types of 
intervention 
      
 
 
   
      
Types of 
outcome 
measures 
      
 
 
   
      
 
INCLUDE   
 
 
EXCLUDE   
 
Reason for 
exclusion 
 
      
Notes:         
 
 
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
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Characteristics of included studies 
Methods 
 
 
Descriptions as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Aim of study (e.g. 
efficacy, equivalence, 
pragmatic) 
            
Design(e.g. parallel, 
crossover, non-RCT)             
Unit of allocation 
(by individuals, cluster/ 
groups or body parts) 
            
Start date 
 
      
 
      
End date 
 
      
 
      
Duration of 
participation 
(from recruitment to last 
follow-up) 
            
Ethical approval 
needed/ obtained for 
study 
   
Yes No Unclear 
            
Notes:         
 
 
 
 
 
 
 
Participants 
 
 Description 
Include comparative information for each intervention or comparison 
group if available 
Location in text 
or source (pg & 
¶/fig/table/other) 
Population description 
(from which study 
participants are drawn) 
            
Setting 
(including location and 
social context)                 
plus country 
            
Inclusion criteria  
 
 
            
Exclusion criteria 
 
 
            
Method of recruitment of 
participants (e.g. phone, 
mail, clinic patients) 
            
Informed consent 
obtained  
 
   
Yes No Unclear 
            
Total no. randomised 
and how were they 
randomised? 
(or total pop. at start of 
study for NRCTs) 
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Post randomization drop 
outs 
Reason:  
  
Clusters 
(if applicable, no., type, no. 
people per cluster) 
            
Baseline imbalances 
 
 
            
Withdrawals and 
exclusions 
(if not provided below by 
outcome) 
            
Age 
 
            
Sex 
 
            
Race/Ethnicity 
 
            
Body weight (kg) 
 
  
BMI (kg/m2) 
 
  
Severity of illness 
 
            
Co-morbidities 
 
            
Other relevant 
sociodemographics 
 
            
Subgroups measured 
 
• non pharma Tx 
• Pharma Tx 
• Pharma vs non Pharma Tx 
• Pts receiving Bariatric Surgery 
• Pts trying to lose weight 
• SGS alone 
• SGS and asymptomatic GS 
      
Subgroups reported 
 
            
Assessment of 
Gallstones 
  
Other details related to 
groups (ie. details of any 
other group or any other 
intervention related to 
patients) 
  
Notes:         
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Intervention groups 
Copy and paste table for each intervention and comparison group  
Total No. of Intervention Groups       □ 
Intervention Group 1 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Group name 
 
            
No. randomised to group 
(specify whether no. people or 
clusters) 
            
Theoretical basis (include 
key references) 
 
            
Description (include sufficient 
detail for replication, e.g. 
content, dose, components) 
            
Duration of treatment period 
            
Timing (e.g. frequency, 
duration of each episode)             
Delivery (e.g. mechanism, 
medium, intensity, fidelity)             
Providers 
(e.g. no., profession, training, 
ethnicity etc. if relevant) 
            
Co-interventions 
 
 
 
 
 
 
 
      
Economic variables 
(i.e. intervention cost, changes 
in other costs as result of 
intervention) 
            
Resource requirements 
(e.g. staff numbers, cold 
chain, equipment) 
            
Integrity of delivery                
(ie intervention itself) 
 
            
Compliance 
 
 
            
Notes:         
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Intervention Group 2 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Group name 
 
            
No. randomised to group 
(specify whether no. people or 
clusters) 
            
Theoretical basis (include 
key references) 
 
            
Description (include sufficient 
detail for replication, e.g. 
content, dose, components) 
            
Duration of treatment period 
            
Timing (e.g. frequency, 
duration of each episode)             
Delivery (e.g. mechanism, 
medium, intensity, fidelity)             
Providers 
(e.g. no., profession, training, 
ethnicity etc. if relevant) 
            
Co-interventions 
 
 
 
 
 
 
 
      
Economic variables 
(i.e. intervention cost, changes 
in other costs as result of 
intervention) 
            
Resource requirements 
(e.g. staff numbers, cold 
chain, equipment) 
            
Integrity of delivery 
(ie intervention itself) 
 
            
Compliance 
 
 
            
Notes:         
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Intervention Group 3 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Group name 
 
            
No. randomised to group 
(specify whether no. people or 
clusters) 
            
Theoretical basis (include 
key references) 
 
            
Description (include sufficient 
detail for replication, e.g. 
content, dose, components) 
            
Duration of treatment period 
            
Timing (e.g. frequency, 
duration of each episode)             
Delivery (e.g. mechanism, 
medium, intensity, fidelity)             
Providers 
(e.g. no., profession, training, 
ethnicity etc. if relevant) 
            
Co-interventions 
 
      
 
 
 
 
      
Economic variables 
(i.e. intervention cost, changes 
in other costs as result of 
intervention) 
            
Resource requirements 
(e.g. staff numbers, cold 
chain, equipment) 
            
Integrity of delivery 
(ie intervention itself) 
 
            
Compliance 
 
 
            
Notes:         
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Outcomes 
Copy and paste table for each outcome. 
No. of outcomes collected    □ 
No. of outcomes reported on   □ 
 
Outcome 1 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Outcome name 
 
            
Time points measured 
(specify whether from start 
or end of intervention) 
            
Time points reported 
 
            
Outcome definition (with 
diagnostic criteria if relevant)             
Person measuring/ 
reporting 
 
            
Unit of measurement  
(if relevant)             
Scales: upper and lower 
limits (indicate whether high  
or low score is good) 
            
Is outcome/tool validated? 
   
Yes No Unclear 
            
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
            
Assumed risk estimate 
(e.g. baseline or population 
risk noted  in Background) 
            
Power 
            
Notes:         
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Outcome 2 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Outcome name 
 
            
Time points measured 
(specify whether from start 
or end of intervention) 
            
Time points reported 
 
            
Outcome definition (with 
diagnostic criteria if relevant)             
Person measuring/ 
reporting 
 
            
Unit of measurement  
(if relevant)             
Scales: upper and lower 
limits (indicate whether high  
or low score is good) 
            
Is outcome/tool validated? 
   
Yes No Unclear 
            
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
            
Assumed risk estimate 
(e.g. baseline or population 
risk noted  in Background) 
            
Power 
            
Notes:         
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Outcome 3 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Outcome name 
 
            
Time points measured 
(specify whether from start 
or end of intervention) 
            
Time points reported 
 
            
Outcome definition (with 
diagnostic criteria if relevant)             
Person measuring/ 
reporting 
 
            
Unit of measurement  
(if relevant)             
Scales: upper and lower 
limits (indicate whether high  
or low score is good) 
            
Is outcome/tool validated? 
   
Yes No Unclear 
            
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
            
Assumed risk estimate 
(e.g. baseline or population 
risk noted  in Background) 
            
Power 
            
Notes:         
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Outcome 4 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Outcome name 
 
            
Time points measured 
(specify whether from start 
or end of intervention) 
            
Time points reported 
 
            
Outcome definition (with 
diagnostic criteria if relevant)             
Person measuring/ 
reporting 
 
            
Unit of measurement  
(if relevant)             
Scales: upper and lower 
limits (indicate whether high  
or low score is good) 
            
Is outcome/tool validated? 
   
Yes No Unclear 
            
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
            
Assumed risk estimate 
(e.g. baseline or population 
risk noted  in Background) 
            
Power 
 
 
      
Notes:         
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Outcome 5 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Outcome name 
 
            
Time points measured 
(specify whether from start 
or end of intervention) 
            
Time points reported 
 
            
Outcome definition (with 
diagnostic criteria if relevant)             
Person measuring/ 
reporting 
 
            
Unit of measurement  
(if relevant)             
Scales: upper and lower 
limits (indicate whether high  
or low score is good) 
            
Is outcome/tool validated? 
   
Yes No Unclear 
            
Imputation of missing data 
(e.g. assumptions made for 
ITT analysis) 
            
Assumed risk estimate 
(e.g. baseline or population 
risk noted  in Background) 
            
Power 
            
Notes:         
 
 
 
 
Other 
 
Study funding sources 
(including role of 
funders) 
 
 
 
      
Possible conflicts of 
interest 
(for study authors) 
 
 
 
      
Notes:         
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Risk of Bias assessment 
See Chapter 8 of the Cochrane Handbook. Additional domains may be added for non-randomised studies. 
 
Domain Risk of bias 
 
Support for judgement 
(include direct quotes where available with 
explanatory comments) 
Location in text or 
source (pg & 
¶/fig/table/other) Low 
risk 
High 
risk 
Unclear 
Random sequence 
generation 
(selection bias) 
   
            
Allocation concealment 
(selection bias) 
 
   
            
Blinding of participants 
and personnel 
(performance bias) 
   
Outcome group: All/      
      
      
(if separate judgement by 
outcome(s) required)    
Outcome group:       
      
      
Blinding of outcome 
assessment 
(detection bias) 
   
Outcome group: All/      
      
      
(if separate judgement by 
outcome(s) required)    
Outcome group:       
      
      
Incomplete outcome data 
(attrition bias) 
 
   
Outcome group: All/      
      
      
(if separate judgement by 
outcome(s) required)    
Outcome group:       
      
 
Selective outcome 
reporting? 
(reporting bias) 
   
            
Other bias 
 
 
   
            
Notes:         
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Data and analysis 
Copy and paste the appropriate table for each outcome, including additional tables for each time point and 
subgroup as required. 
 
For RCT/CCT 
Binary (Dichotomous) outcome  
 
1. All cause mortality at max follow-up 
2. Proportion of pts with GS-related complications 
3. Proportion of pts with Tx-related complications 
4. Proportion of pts with GS 
5. Porportion of pts Tx by cholecystectomy 
6. Changes in biliary lithogenicity 
7. Tx stoppage or withdrawal 
 
1. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end of 
intervention) 
            
Results (ie. 2 x 2 table) Intervention Comparison 
      
No. with event Total in group No. with event Total in group 
                        
Any other results reported 
(e.g. odds ratio, risk 
difference, CI or P value) 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups or 
body parts) 
            
Statistical methods used 
and appropriateness of 
these (e.g. adjustment for 
correlation) 
            
Reanalysis required? 
(specify, e.g. correlation 
adjustment) 
   
Yes No Unclear 
            
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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2. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end of 
intervention) 
            
Results  (ie. 2 x 2 table) Intervention Comparison 
      
No. with event Total in group No. with event Total in group 
                        
Any other results reported 
(e.g. odds ratio, risk 
difference, CI or P value) 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups or 
body parts) 
            
Statistical methods used 
and appropriateness of 
these (e.g. adjustment for 
correlation) 
            
Reanalysis required? 
(specify, e.g. correlation 
adjustment) 
   
Yes No Unclear 
            
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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3. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end of 
intervention) 
            
Results  (ie. 2 x 2 table) Intervention Comparison 
      
No. with event Total in group No. with event Total in group 
                        
Any other results reported 
(e.g. odds ratio, risk 
difference, CI or P value) 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups or 
body parts) 
            
Statistical methods used 
and appropriateness of 
these (e.g. adjustment for 
correlation) 
            
Reanalysis required? 
(specify, e.g. correlation 
adjustment) 
   
Yes No Unclear 
            
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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4. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end of 
intervention) 
            
Results  (ie. 2 x 2 table) Intervention Comparison 
      
No. with event Total in group No. with event Total in group 
                        
Any other results reported 
(e.g. odds ratio, risk 
difference, CI or P value) 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups or 
body parts) 
            
Statistical methods used 
and appropriateness of 
these (e.g. adjustment for 
correlation) 
            
Reanalysis required? 
(specify, e.g. correlation 
adjustment) 
   
Yes No Unclear 
            
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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For RCT/CCT 
Continuous outcome 
 
1. Quality of life 
2. Weight lost in Kg 
3. % weight lost 
4. Change in BMI 
1. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end 
of intervention) 
            
Post-intervention or 
change from baseline? 
            
Results Intervention Comparison 
      
Mean SD (or other 
variance, 
specify)  
No. 
participants 
Mean SD (or other 
variance, 
specify) 
No. 
participants 
 
 
                              
Any other results 
reported (e.g. mean 
difference, CI, P value) 
 
 
 
 
 
      
No. missing 
participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis 
(individuals, cluster/ 
groups or body parts) 
            
Statistical methods 
used and 
appropriateness of 
these (e.g. adjustment 
for correlation) 
 
 
 
 
      
Reanalysis required? 
(specify)    
Yes No Unclear 
      
      
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
 
 
 
      
Notes:         
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2. 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end 
of intervention) 
            
Post-intervention or 
change from baseline? 
            
Results Intervention Comparison 
      
Mean SD (or other 
variance, 
specify)  
No. 
participants 
Mean SD (or other 
variance, 
specify) 
No. 
participants 
 
 
 
                              
Any other results 
reported (e.g. mean 
difference, CI, P value) 
 
 
 
 
 
      
No. missing 
participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis 
(individuals, cluster/ 
groups or body parts) 
            
Statistical methods 
used and 
appropriateness of 
these (e.g. adjustment 
for correlation) 
      
 
 
 
 
      
Reanalysis required? 
(specify)    
Yes No Unclear 
      
      
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
 
 
 
 
      
Notes:         
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For RCT/CCT 
Other outcome ie Count data outcome  
1. No. of GS related adverse events 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end 
of intervention) 
            
No. participant Intervention Control 
 
            
Results 
ie no. of events 
Intervention 
result 
SD (or other 
variance) Control result SD (or other variance) 
      
                        
Overall results SE (or other variance) 
            
Any other results 
reported  
 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups 
or body parts) 
            
Statistical methods used 
and appropriateness of 
these 
            
Reanalysis required? 
(specify)    
Yes No Unclear 
      
      
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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Other outcome ie Count data outcome  
2. No. of Tx related adverse events 
 
 Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison 
 
            
Outcome 
 
            
Subgroup (analyses) 
 
            
Time point 
(specify from start or end 
of intervention) 
            
No. participant Intervention Control 
 
            
Results 
ie no. of events 
Intervention 
result 
SD (or other 
variance) Control result SD (or other variance) 
      
                        
Overall results SE (or other variance) 
            
Any other results 
reported  
 
            
No. missing participants 
 
                  
Reasons missing 
 
                  
No. participants moved 
from other group 
                  
Reasons moved 
 
                  
Unit of analysis (by 
individuals, cluster/groups 
or body parts) 
            
Statistical methods used 
and appropriateness of 
these 
            
Reanalysis required? 
(specify)    
Yes No Unclear 
      
      
Reanalysis possible? 
   
Yes No Unclear 
      
      
Reanalysed results 
 
            
Notes:         
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Other information 
 
Description as stated in report/paper 
 
Location in text 
or source (pg & 
¶/fig/table/other) 
Key conclusions of study 
authors 
 
 
 
 
 
 
 
      
References to other 
relevant studies 
 
 
 
 
 
 
      
Correspondence required 
for further study 
information (from whom, 
what and when) 
 
 
 
 
Funding source 
 
 
 
 
 
Miscellaneous comments 
from study authors 
 
 
 
 
 
 
Notes:         
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Appendix 3. Excluded studies with reason 
Study Reason 
Acalovschi 4  Longitudinal observation study. 
Al-Jiffry 7 not a randomised controlled trial. 
Arffmann 12    did not assess incidence of gallstones; intervention duration too short (2 wks). 
Baudet 20 looked at TPN and intervention duration between 2-3 wks. 
Bell 22  review article 
Cometta 41 intervention duration too short for most participants (mean 2 wks). 
Davidson 46 did not assess incidence of gallstones, or any hepato-biliary components. 
De Oliveira 85 retrospective observation study. 
Desbeaux 48  review article. 
Einarsson 53  intervention duration too short (3 wks); did not assess incidence of gallstones. 
Fischer 58 assessed gallstone dissolution with a short intervention lasting 10-12 days. 
Fobi 60 observation study. 
Frenkiel 62 randomised intervention trial for gallstones dissolution. 
Fuller 65 observation study. 
Hamad 73 not a randomised controlled trial. 
Heim-Duthoy 75 assessed gallstone incidence but intervention duration too short (14 days). 
Henriksson 76 intervention trial in participants with existing gallstones and cholecystectomy. 
Heshka 77  not a randomised controlled trial. 
Hoy 81  met inclusion criteria but did not receive required information from authors. 
Jonkers 91 Crossover design assessing gallbladder dysmotility. Only presented data at 
end of crossover period.  
Kamrath 94 not a randomised controlled trial. 
Kiewiet 99  retrospective observation study. 
Klass 103 intervention duration too short (3 wks). 
Kurata 111 retrospective analysis of symptomatic gallstones requiring hospitalisation. 
Lee 121 animal study. 
Liddle 128 not a randomised controlled trial. 
Lustig 130 some participants had undergone a cholecystectomy. 
Mason 135  qualitative study. 
Mazzella 138  did not assess interventions for primary prevention of gallstones. However, 
information on adverse events included in this review. 
Mok 146,147  did not assess interventions for primary prevention of gallstones. However, 
information on adverse events included in this review. 
Nagem 151 longitudinal observation study. 
Nagem 152 prospective observation study. 
Neitlich 154  not a randomised controlled trial. 
Nougou 155 prospective observation study. 
O’Donnell 156  intervention duration too short (1 wk). 
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Study Reason 
Östlund 169 longitudinal observation study. 
Oria 157  retrospective observation study. 
Pausawasdi 162 animal study. 
Pavel 163 case-control study of gallstone risk with sun exposure. 
Pazzi 164 case-control study of gallstone risk with nonsteroidal anti-inflammatory drug 
use. 
Pitt 167 not a randomised controlled trial. 
Rhodes 176 intervention study in participants with gallstones. 
Rubin 177 intervention duration too short (48 hours). 
Rudnicki 178 nested case-control study. 
Scott 185 not a randomised controlled trial. However, information on adverse events 
included in this review. 
Sengupta 187 intervention duration too short (8 hour treatments on 3 occasions). 
Shiffman 189  prospective observation study. 
Shiffman 190 prospective observation study. 
Sitzmann 195 intervention duration too short; did not report on gallstone incidence. 
Spirt 201 not a randomised controlled trial. 
Sterling 204  retrospective observation study. 
Storti 211 used self-report. 
Sorensen 198,199,200 surgical interventions. 
Tarantino 215 prospective observation study. 
Tazuma 216  not a randomised controlled trial. 
Trouillot 221 did not assess interventions for primary prevention of gallstones. 
Utter 235 intervention duration too short (several hours). 
Utter 236  did not assess interventions for primary prevention of gallstones. 
Venneman 238 review article. 
Vezina 239 not a randomised controlled trial. 
Villegas 240  not a randomised controlled trial. 
Wang 246 not a randomised controlled trial. 
Wilund 255 animal study. 
Yang 258 not a randomised controlled trial. 
Zapata 259  not a randomised controlled trial. 
Zoli 261 not a randomised controlled trial; intervention duration too short. 
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Appendix 4. Characteristics of included studies  
Ai 2003   
Methods Randomised comparison of UCDA versus control. 
Participants • Mean age: 55.7 years (UDCA), 56 years (control). 
• Females: 42% (UDCA), 44% (control). 
• Mean weight: not reported. 
• Mean BMI 21.1 kg/m2 (UDCA), 21.1 kg/m2 (control). 
Interventions • Intervention: 600 mg UDCA/day for 24 weeks. 
• Control: did not receive anything during these 24 weeks. 
Outcomes Formation of gallstones, values of hemolysis markers (haptoglobin, hemoglobin, 
lactate dehydrogenase, reticulocyte, total bilirubin), gallbladder contractility, blood 
transfusion volume, heart-lung machine running time. 
Duration of follow 
up 60 months. 
Collateral 
interventions None. 
Notes • No additional information received from the primary investigators. 
• Country: Japan. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk
 unclear. 
Allocation concealment 
(selection bias) 
Unclear risk
 
unclear. 
Blinding of participants and 
personnel (performance bias) 
High risk
 
not placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Unclear risk
 
unclear. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow-up are not clearly 
included in the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Unclear risk
 
No information on funding provided. 
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Broomfield 1988   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 39.8 years (UDCA), 35.7 years (placebo). 
• Females: 74% (UDCA), 78% (placebo). 
• Mean weight: 105.7 kg (UDCA), 106.2 kg (placebo). 
• Mean BMI (not reported). 
Interventions • Intervention: 1200 mg UDCA/day for 16 weeks. 
• Control: identical placebo for 16 weeks. 
Outcomes Bile cholesterol saturation, biliary glycoprotein and biliary prostaglandin E2 
concentrations, formation of gallstones (or crystals or microstones) and weight loss. 
Duration of 
follow up 19 weeks. 
Collateral 
interventions 
Very low calorie low fat diet (520 kcal, 55 g protein, 79 g carbohydrate, 1 g fat, plus 
supplemental vitamins, trace elements, minerals) and 2 litres non-caloric liquid daily. 
Notes • The trial includes a third intervention group (1300 mg aspirin/day) that was 
excluded from the main meta-analyses. 
• No additional information received from the primary investigators. 
• Country: USA. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow-up were not clearly 
described or accounted for. 
Selective reporting (reporting 
bias) 
High risk
 
Clinically relevant outcomes not clearly 
reported at the end of follow-up. 
Other bias Low  risk
 
Funding source: National Institutes of Health 
(grant). 
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De Filippo 1993   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 38 years (UCDA and placebo). 
• Females: 78% (UCDA and placebo). 
• Mean weight: 105.2 kg (UDCA), 100.8 kg (placebo). 
• Mean BMI: 39.0 kg/m2 (UDCA), 38.3 kg/m2 (placebo). 
Interventions • Intervention: 600 mg to 900 mg UDCA/day for 16 weeks. 
• Control: identical placebo for 16 weeks. 
Outcomes Formation of gallstones (or sludge or microlithiasis), weight loss, blood pressure, 
blood parameters (blood urea nitrogen, glucose, total protein, total and direct 
bilirubin, triglycerides, cholesterol, transaminase, alkaline phosphatase, gamma-
glutamyl transferase) and blood erythrocyte, haemoglobin, hematocrit, leukocytes 
and platelets. 
Duration of 
follow up 16 weeks. 
Collateral 
interventions 
Low calorie high fat diet (1000 to 1200 kcal, 60 to 70 g protein, 100 to 170 g 
carbohydrate, 20 to 43 g fat [6% saturated], 35 to 40 g fibre, 165 to 220 mg 
cholesterol). 
Notes • Additional information received from the primary investigators. 
• Country: Italy. 
 Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
All participants completed the trial and were 
reported on. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Unclear risk
 
Funding source: not described. 
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Festi 1998   
Methods Randomised comparison of very low calorie high fat diet versus very low calorie low 
fat diet. 
Participants • Mean age: 40.5 years (intervention and control group). 
• Females: 63% (intervention and control group). 
• Mean weight: not reported. 
• Mean BMI 41.6 kg/m2 (intervention and control group). 
Interventions • Intervention: very low calorie high fat diet (577 kcal, 55.0 g protein, 61.7 g 
carbohydrate, 12.2 g fat, plus vitamins, trace elements and mineral supplements); 
at least 2 litres of non-caloric liquids per day for 12 weeks 
• Control: very low calorie low fat diet (535.2 kcal, 44.4 g protein, 82.2 g 
carbohydrate, 3.0 g fat, plus vitamins, trace elements and mineral supplements); 
at least 2 litres of non-caloric liquids per day for 12 weeks. 
Outcomes Formation of gallstones (or cholesterol crystals), gallbladder motility (gallbladder 
emptying, fasting volume), biliary lipid composition and cholesterol saturation index 
(bile acid and phospholipid molar percentages), weight loss and compliance. 
Duration of 
follow up 12 weeks. 
Collateral 
interventions None. 
Notes • The trial includes a follow-up phase in which all participants followed a low calorie 
high fat diet for 12 weeks. The data from this follow up period are not included in 
this review. 
 
• Additional information received from the primary investigators. 
 
• Country: Italy. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 
Random numbers. 
Allocation concealment 
(selection bias) 
Unclear risk
 
Not described. 
Blinding of participants and 
personnel (performance bias) 
Unclear risk
 
Blinding of participants and personnel not 
described. 
Blinding of outcome assessment 
(detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow-up were not clearly 
accounted for. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Unclear risk
 
Unclear. 
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Gebhard 1996   
Methods Randomised comparison of high fat diet versus very low fat low calorie diet. 
Participants • Mean age: 40 years (intervention), 40 years (control). 
• Females: 71% (intervention), 83% (control). 
• Mean weight: 114 kg (intervention), 105 kg (control). 
• Mean BMI: 36 kg/m2 (intervention), 37 kg/m2 (control). 
Interventions • Intervention: low calorie high fat diet (900 kcal, 90 g protein, 67 g carbohydrate, 
30 g fat and 90 mg cholesterol) for 12 weeks. 
• Control: very low calorie low fat diet (520 kcal, 50 g protein, 79 g carbohydrate, 
less than 2 g fat and 30 mg cholesterol) for 12 weeks. 
Outcomes Formation of gallstones (or cholesterol crystals), gallbladder motility (gallbladder 
emptying, fasting volume), bile saturation index (bile phospholipid molar ratio), blood 
lipids, weight loss and compliance. 
Duration of 
follow up 24 weeks. 
Collateral 
interventions Oral supplements with the recommended daily allowances for vitamins/minerals. 
Notes • No additional information received from the primary investigators. 
 
• Conventional foods were resumed after the first 12 weeks and patients followed 
up for another 12 weeks. Data on gallstones from the first 12 weeks is included. 
 
• Country: USA. 
 
• Human Subjects Subcommittee encouraged cessation of enrolment because two 
of the participants with gallstones were symptomatic. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk
 
Not described. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or control. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Administration of blinded identically appearing 
packets containing the intervention or control. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
All participants completed the trial and were 
reported on. 
Selective reporting (reporting 
bias) 
High risk
 
Clinically relevant outcomes are not reported 
at the end of follow-up. 
Other bias Low  risk
 
Funding source: Department of Veterans 
Affairs Research Program (Sandoz Nutrition, 
Minneapolis provided the diets). 
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Marks 1996   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 41.4 years (UDCA), 39.4 years (placebo). 
• Females: 75% (UDCA), 63% (placebo). 
• Mean weight: 99.5 kg (UDCA), 114.2 kg (placebo). 
• Mean BMI: 34.8 kg/m2 (UDCA), 37.0 kg/m2 (placebo). 
Interventions • Intervention: 1200 mg UDCA/day for 12 weeks. 
• Control: identical placebo for 12 weeks. 
Outcomes Bile saturation index, biliary glycoprotein and biliary prostaglandin E2 concentrations, 
biliary lipids, gallbladder contraction, formation of gallstones (or crystals), weight loss 
and compliance. 
Duration of 
follow up 12 weeks. 
Collateral 
interventions Both groups followed a very low calorie diet (520 kcal; macronutrients unspecified). 
Notes • The trial includes a third intervention group (1600 mg ibuprofen/day) that was 
excluded from the main meta-analyses. 
 
• No additional information received from the primary investigators. 
 
• Country: USA 
 
• Recruitment was terminated early in this trial due to slow recruitment and larger 
than expected drop out rates. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Losses to follow-up not clearly described for 
each group or accounted for in the analyses. 
Selective reporting (reporting 
bias) 
High risk
 
Clinically relevant outcomes not reported at the 
end of follow-up. 
Other bias High risk
 
Funding source: not reported. 
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Mendez-Sanchez 2001   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 37.8 years (UDCA), 39.7 years (placebo). 
• Females: 100% (UCDA and placebo). 
• Mean weight: 79.8 kg (UDCA), 81.9 kg (placebo). 
• Mean BMI: 34.2 kg/m2 (UDCA), 33.4 kg/m2 (placebo). 
Interventions • Intervention: 1200 mg UDCA/day for 6 weeks. 
• Control: identical placebo for 6 weeks. 
Outcomes Formation of gallstones, bile saturation index, nucleation time, weight loss, 
compliance. 
Duration of 
follow up 6 weeks. 
Collateral 
interventions 
Low calorie diet (1200 kcal, 60 g protein [20 %], 180 g carbohydrate [60 %] , 27 g fat 
[20 %]) plus 1 litre water daily. 
Notes • The trial includes a third intervention group, (11.3 g omega-3 fatty acids/day) that 
was excluded from the main meta-analyses. 
 
• No additional information received from the primary investigators. 
 
• Country: Mexico. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow up were not clearly 
described for each group or accounted for in 
the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Low  risk
 
Funding source: partially funded by National 
Council on Science and Technology in Mexico 
(CONACyT). 
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Miller 2003   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 34.1 years (UDCA), 36.3 years (placebo). 
• Females: 81% (UDCA), 85% (placebo). 
• Mean weight: 137 kg (UDCA), 136 kg (placebo). 
• Mean BMI: 43.7 kg/m2 (UDCA), 44.3 kg/m2 (placebo). 
Interventions • Intervention: 500 mg UDCA/day for 24 weeks. 
• Control: identical placebo for 24 weeks. 
Outcomes Formation of gallstones, weight loss, compliance. 
Duration of 
follow up 24 months. 
Collateral 
interventions 
None, however 50% received vertical banded gastroplasty and 50% received 
adjustable gastric banding within three days of intervention initiation. 
Notes • Additional information received from the primary investigators. 
• Country: Austria. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
Participants lost to follow-up were accounted 
for in the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Low  risk
 
Funding source: no funding received. 
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Moran 1997   
Methods Randomised comparison of UDCA versus fibre. 
Participants • Mean age: 39 years (UDCA), 38 years (fibre). 
• Females: 83% (UDCA), 83% (fibre). 
• Mean weight: 89.7 kg (UDCA), 85.8 kg (placebo). 
• Mean BMI: 34 kg/m2 (UDCA), 35 kg/m2 (fibre). 
Interventions • Intervention: 750 mg UDCA/d plus fibre placebo for 8 weeks. 
• Control: 15 g fibre as psyllium plantago plus UDCA placebo for 8 weeks. 
Outcomes Formation of gallstones, crystal determination, weight loss, compliance. 
Duration of 
follow up 8 weeks. 
Collateral 
interventions 
Both groups followed a low calorie diet (calculated as - 500 kcal their total energy 
requirements. This diet comprised 15% protein, 60% carbohydrate, 25% fat, 15% 
fibre [20g]). 
Notes • Most information was extracted from the 1997 publication. 
• Additional information received from the primary investigators. 
• Country: Mexico. 
 Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
intervention or placebo (by an external 
monitor). 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
All participants completed the trial and were 
reported on. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Low  risk
 
Source of funding: partially funded by National 
Council on Science and Technology in Mexico 
(CONACyT). 
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Shiffman 1995   
Methods Randomised comparison of UDCA versus placebo. 
Participants • Mean age: 40.3 years (UDCA), 39.8 years (placebo). 
• Females: 66% (UDCA), 66% (placebo). 
• Mean weight: 127.8 kg (UDCA), 128.7 kg (placebo). 
• Mean BMI: 44.1 kg/m2 (UDCA), 44.5 kg/m2 (placebo). 
Interventions • Intervention: 300/600/1200 mg UDCA/day for 16 weeks. 
• Control: identical placebo for 16 weeks. 
Outcomes Formation of gallstones (or crystals or microstones), gallbladder sludge, bile analysis, 
weight loss and compliance. 
Duration of 
follow up 16 weeks. 
Collateral 
interventions 
All groups followed a very low calorie diet (520 kcal, 50 g protein, 79 g carbohydrate, 
1g to 3 g fat, plus supplemental vitamins and minerals supplying 100% to 150% US 
recommended daily allowance were provided and consumption of non-caloric fluids 
(water, diet drinks) was unlimited. 
Notes • The three intervention groups with different doses of UDCA were combined to form 
one group and were compared to the placebo group. 
• Additional information received from the primary investigators. 
• Country: USA. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow-up from each 
intervention group were not clearly described 
or accounted for in the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias High risk
 
The sponsoring pharmaceutical company 
carried out the data collection/analysis. 
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Sugerman 1995   
Methods Randomised comparison of UCDAversus placebo. 
Participants • Mean age: 36.4 years (UDCA), 37.4 years (placebo). 
• Females: 80% (UDCA), 79% (placebo). 
• Mean weight: 137 kg (UDCA), 144 kg (placebo). 
• Mean BMI: 49.0 kg/m2 (UDCA), 50.7 kg/m2 (placebo). 
Interventions • Intervention: 300/600/1200 mg UDCA/day for 24 weeks. 
• Control: identical placebo for 24 weeks. 
Outcomes Formation of gallstones, efficacy of 3 doses of UDCA, weight loss, compliance. 
Duration of 
follow up 6 months (12 months in a subset of participants but this is not included in the review). 
Collateral 
interventions 
None, however all participants received Roux-en-Y gastric bypass 4 days before 
intervention initiation. 
Notes • The three intervention groups with different doses of UDCA were combined to form 
one group and were compared to the placebo group. 
• Additional information received from the primary investigators. 
• Country: USA. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
Participants lost to follow-up were accounted 
for in the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias High risk
 
Funding source: pharmaceutical company. 
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Williams 1993   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: not given. 
• Females: not given. 
• Mean weight: not given. 
• Mean BMI: not given. 
Interventions • Intervention: 10 mg/kg UDCA/day for up to 18 months. 
• Control: identical placebo for up to 18 months. 
Outcomes Formation of gallstones, weight loss, compliance. 
Duration of 
follow up 18 months. 
Collateral 
interventions 
None, however all participants received vertical banded gastroplasty six weeks before 
intervention initiation. 
Notes • No additional information received from the primary investigators. 
• Country: Canada. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome assessment 
(detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Although all the numbers and reasons for 
drop-outs in all intervention groups were 
described, a high non-compliance was 
observed. 
Selective reporting (reporting 
bias) 
High risk
 
Clinically relevant outcomes not clearly 
defined and reported. 
Other bias High risk
 
Funding source: partially sponsored by a 
pharmaceutical company. 
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Worobetz 1993   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 33.5 years (UDCA), 33.9 years (placebo). 
• Females: 69% (UDCA), 69% (placebo). 
• Mean weight: 146.8 kg (UDCA), 142.5 kg (placebo). 
• Mean BMI: not given. 
Interventions • Intervention: 1000 mg UDCA/day for 12 weeks. 
• Control: identical placebo for 12 weeks. 
Outcomes Formation of gallstones (or cholesterol crystals), bile composition, blood parameters 
(complete blood count, electrolytes, fasting cholesterol and triglycerides, fasting 
glucose, creatinine, albumin, biliruin, prothrombin time, aspartate aminotransferase, 
alkaline phosphatase), weight loss, compliance. 
Duration of 
follow up 12 weeks. 
Collateral 
interventions 
None, however all participants received vertical band gastroplasty 4 days before 
intervention initiation. 
By the 4th postoperative day most participants tolerated a pureed diet (832 kcal, 
26.0% protein, 52.0% carbohydrate, 22.0% fat) consumed as 9 meals per day for 4 
weeks. They then advanced to a soft diet (995 kcal, 24.5% protein, 44.0% 
carbohydrate, 31.5% fat) consumed as 3 meals per day. 
Notes • No additional information received from the primary investigators. 
• Country: Canada. 
 Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
Participants lost to follow-up were described for 
each group and accounted for in the analyses. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias Low  risk
 
Funding source: partial funding provided by the 
Medical Research Council of Canada. 
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Wudel 2002   
Methods Randomised comparison of UCDA versus placebo. 
Participants • Mean age: 38 years (UCDA and placebo). 
• Females: 85% (UCDA and placebo). 
• Mean weight: 159 kg (UCDA and placebo). 
• Mean BMI: not given. 
Interventions • Intervention: 600 mg UDCA/day for 24 weeks. 
• Control: identical placebo for 24 weeks. 
Outcomes Formation of gallstones, gallbladder emptying, cholesterol saturation index, weight 
loss, compliance. 
Duration of 
follow up 12 months. 
Collateral 
interventions 
None, however all participants received Roux-en-Y gastric bypass before 
intervention initiation. 
Notes • The trial includes a third intervention group (600 mg ibuprofen/day) that was 
excluded from the main meta-analyses. 
• No additional information received from the primary investigators. 
• Country: USA. 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low  risk
 
Table of random numbers. 
Allocation concealment 
(selection bias) 
Low  risk
 
Administration of blinded containers with the 
active intervention or placebo. 
Blinding of participants and 
personnel (performance bias) 
Low  risk
 
Placebo controlled. 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blinded outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk
 
Participants lost to follow-up were not clearly 
accounted for in the analyses, and a high 
non-compliance was observed. 
Selective reporting (reporting 
bias) 
Low  risk
 
Clinically relevant outcomes defined and 
reported. 
Other bias High risk
 
Funding source: partial funding provided by a 
Clinical Nutrition Research Unit Award and 
partially funded by a pharmaceutical 
company. 
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Appendix 5. Meta-analyses assessing risk of bias 
 
Meta-analyses assessing different components of bias with regard to gallstone formation in 
patients receiving UDCA versus control interventions based on:  
 
Allocation concealment stratification 
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Blinding methods stratification (upper) and attrition bias stratification (lower) 
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Outcomes reporting stratification (upper) and other bias (lower) 
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Good outcome (upper) and poor outcome analysis (lower) 
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The Cochrane Hepato-Biliary Group 
Title Registration Form 
 
 
 
Please complete this form to outline your proposal for a Cochrane systematic review. E-mail the 
completed form to dnikolov@ctu.rh.dk, or send to Dimitrinka Nikolova, Managing Editor, Cochrane 
Hepato-Biliary Group, Rigshospitalet, Dept. 33.44, Blegdamsvej 9, DK-2100 Copenhagen Ø 
Denmark, Tel. +45 3545 7169. Fax +45 3545 7101. http://ctu.rh.dk/chbg. 
 
 
 
 
 
Proposed title (see Handbook section 4.2.1) 
 
Non-pharmacological and pharmacological interventions for the primary prevention of gallbladder stones 
 
 
Contact person (see Handbook section 4.2.3) 
 
Name: Caroline Stokes 
 
 
Review proposal and inclusion criteria: (see Handbook chapter 5) 
 
Motivation for 
the review: 
There are two main motivators for this review:  
1. To ascertain whether existing evidence supports the use of non-pharmacological 
and pharmacological interventions (as opposed to surgical) in the prevention of 
gallbladder stones.  
2. To contribute to the development of the European clinical practice guidelines for 
gallbladder stones through the Cochrane review publication. 
  
 
Review 
objective: 
The objective of this review is to evaluate the efficacy of non-pharmacological and 
pharmacological interventions in the primary prevention of gallbladder stones in adults.  
 
Types of study: 
(section 5.5) 
In our analysis we plan to include all randomized controlled trials (RCTs) irrespective of 
blinding, language, sample size, or publications status. Controlled clinical trials (CCTs) 
where quasi-randomization methods have been used, such as day of the week, date of 
birth, medical record number may also be considered.  
 
Participants / 
population: 
(section 5.2) 
This review will include both hospital and community based male and female adults (>18 
years) from all ethnicities, who have a BMI > 25 kg/m2 and who do not have gallbladder 
stones as confirmed by ultrasonography. However studies using self-report measures will 
also be included when relating specifically to cholecystectomy as they are deemed 
reliable.  
The time frame when searching the literature will therefore include studies from 1970 to 
present, coinciding with the introduction of ultrasonography.  
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Intervention: 
(section 5.3) 
Trials will be considered where at least one arm of the study has been allocated to receive 
a pharmacological intervention (irrespective of the time, dose, or pharmacological class of 
the administered drug) or a non-pharmacological intervention for prophylaxis against 
gallstone formation following a standard (within trial) protocol. This may include the 
following interventions (single or multiple per trial): 
• pharmacological (e.g. ursodeoxycholic acid, non-steroidal anti inflammatory 
drugs) 
• non-pharmacological (e.g. calorie restriction, dietary fibre or lipid modification, 
physical activity interventions). 
 
Settings: both community and hospital based interventions will be considered.   
 
For the above interventions, special consideration will be given to what is delivered (e.g. 
drug preparation), as well as to the intensity, frequency and route of administration. 
Pharmacological regimens for gallstone prevention are usually taken once or twice per 
day – this discrepancy is deemed unlikely to cause substantial differences in treatment 
effect thus will not be separated.  
 
Duration: the duration period will vary between studies, however minimum standards will 
be set for determining inclusion criteria (e.g. interventions lasting ≥ 3 months). Therefore, 
in terms of dietary-related interventions, single meal studies will be excluded as these are 
deemed to have a minimal impact on prevalence of gallbladder stones. 
 
Between-study variation may also exist for the dosage or quantity of an intervention, 
particularly with regards pharmacological interventions. Where varying pharmacological 
doses exist, these may be grouped together if significances are observed in all treatment 
levels, alternatively doses may be grouped based on predetermined clusters such as low, 
medium or high. For example, ursodeoxycholic acid is often prescribed as mg/kg body 
weight or in standard doses ranging from 300, 500, 600,1000 or 1200 mg/day and can 
therefore be grouped into the following: low dose (≤ 600 mg/day) and medium dose > 600 
mg/day). Our understanding is that high doses of ursodeoxycholic acid have not been 
investigated in RCTs. 
 
 
Acceptable comparator groups will include:  
(1) inactive control intervention such as placebo, no treatment  
(2) active control intervention such as a variant of the same intervention, other 
pharmacological or non-pharmacological treatments. 
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Outcomes and 
adverse effects: 
(section 5.4) 
Types of outcomes 
Main outcomes: 
• Formation of gallbladder stones 
• Cholecystectomy treatment 
• Adverse events (e.g. mortality, morbidity) 
• Quality of life  
• Attrition rates/compliance  
• Effect of interventions on weight loss (which will inform 
part of our review looking at gallstone prevention during weight loss)    
 
Primary outcomes:  
(1) Formation of gallbladder stones (asymptomatic or symptomatic) as assessed by 
ultrasonography. Results reporting gallstones cases per group will be included 
(e.g. percentage of gallstones cases per group; Odds Ratio values; 95% 
Confidence Intervals, P values). Studies that do not report on gallstone formation 
as an outcome will not be included.  
 
(2) Treatment with cholecystectomy (which is also a proxy for symptomatic 
gallstones), as measured by ultrasonography or self report measures. Results on 
patients who underwent cholecystectomy which are reported as per the first 
primary outcome will be included.  
 
(3) Occurrence (number and type) of adverse events during or within a reasonable 
post intervention time frame and will include for example, patient and clinician 
reporting of side effects, poor quality of life scores, morbidity, and mortality. An 
adverse event based on the ICH definitions and standards for expedited reporting 
(ICH 1995) is defined as any untoward medical occurrence that does not have a 
causal relationship with the particular treatment and can include any unfavourable 
and unintended sign (e.g. abnormal laboratory findings), symptoms or disease 
which is temporarily associated with the use of the respective medicinal product 
under investigation, regardless of whether it is related to this medicinal product. 
The ICH describe a severe adverse event as that which results in death; is life 
threatening; requires hospitalisation or prolongation of existing hospitalisation; 
results in persistent or significant disability/incapacity or any medical event which 
may jeopardise the patient or require an intervention to prevent it. Evidence of 
adverse events will not only be sought from RCTs but also from open studies and 
case reports.  
 
 
 
Secondary outcomes:  
2. The effect of an intervention on bile lithogenicity (changes in physiological 
parameters of bile composition indicative of an increased risk of gallstones, e.g. 
bile nucleation time, biliary cholesterol saturation, cholesterol crystals, bile acid 
synthesis/pool – assessed through the analysis of patient bile).  
3. The effect of the intervention on weight loss (e.g. weight, BMI and percent weight 
loss from baseline weight). 
4. Attrition rates and/or compliance with study intervention (to determine potential 
bias in the data analysed from remaining subjects [e.g. was an Intention To Treat 
analysis used], as well as the feasibility of an intervention in clinical practice). 
5. Quality of life (e.g. subjective measures with validated questionnaires such as 
Short Form 36, Ware Med Care 1995 33:AS264-AS279). 
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Timing of outcome measurements  
Outcome measures will be assessed post intervention. For studies with differing time 
frames (e.g. for follow up) the following intervals will be used: short term (≤ 3 months), 
medium term (between 4-9 months) and long term (> 10 months). 
 
Subgroup 
analyses: 
(section 9.6) 
If enough studies are found to justify subgroup analyses, the following subgroups could be 
investigated further for effect modification:  
1. Intervention type  
a. pharmacological therapies (different types and dosage) 
b. non-pharmacological therapies (in combination and/or alone) 
c. pharmacological versus non-pharmacological therapy 
2. Intervention type based on patients receiving bariatric surgery versus those not 
receiving bariatric surgery 
3. Intervention type based on patients actively trying to lose weight versus those not 
trying to lose weight 
4. Outcome of symptomatic gallstones and/or cholecystectomy versus asymptomatic 
gallstones  
5. Quality of bias control 
6. Treatment duration/duration of follow up 
7. Gender - as gallstones are more prevalent amongst females (Portincasa et al, 
Lancet 2006 368:230-239) 
8. Different geographical locations and/or ethnicities due to the fact that both ethnic 
and geographical disparities exist regarding the prevalence of gallstones 
(Lammert & Miquel Liver Int 2008 28:935-947) 
 
A discussion of cost and cost-effectiveness of the interventions will be included in our 
review.  
 
Sensitivity Analysis 
If appropriate, a sensitivity analysis will be performed to explore the influence of the 
following factors on effect size: 
• Publication status (excluding unpublished studies) 
• Study quality (excluding studies of low quality e.g. that do not provide the drop out 
rate) 
• Blinding (removal of unclear or inadequate) 
• Allocation concealment (removal of unclear or inadequate allocation procedure) 
• Duration (impact of short and long duration) 
• Language of publication   
 
Other 
information: 
From our experience in clinical practice, consumers who are at a high risk of gallstones 
are often reluctant to undergo prophylactic cholecystectomy but frequently request for 
alternative (particularly non-pharmacological) interventions instead. We hope this review 
will help to inform clinical practice by providing a systematic evaluation of the evidence 
base relating to non-surgical (pharmacological and non-pharmacological) interventions for 
the primary prevention of gallbladder stones.   
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Authors’ responsibilities 
 
 
By completing this form, you accept responsibility for preparing, maintaining and updating the review in 
accordance with Cochrane Collaboration policy. The Cochrane Review Group (CRG) will provide as much 
support as possible to assist with the preparation of the review. 
 
A draft protocol must be submitted to the CRG within six months. If drafts are not submitted before the agreed 
deadlines, or if we are unable to contact you for an extended period, the CRG has the right to de-register the 
title or transfer the title to alternative authors. The CRG has the right to de-register or transfer the title if it 
does not meet the standards of the CRG and/or The Cochrane Collaboration. 
 
You accept responsibility for maintaining the review in light of new evidence, comments and criticisms, and 
other developments, and updating the review at least once every two years, or, if requested, transferring 
responsibility for maintaining the review to others as agreed with the CRG. 
 
 
Publication in the Cochrane Database of Systematic Reviews 
 
 
The support of the CRG in preparing your review is conditional upon your agreement to publish the protocol, 
finished review and subsequent updates the Cochrane Database of Systematic Reviews. By completing this 
form you undertake to publish this review in the Cochrane Database of Systematic Reviews before publishing 
elsewhere (concurrent publication in other journals may be allowed in certain circumstances with prior 
permission from the CRG). 
 
I understand the commitment required to undertake a Cochrane review, and agree to publish 
first in the Cochrane Database of Systematic Reviews. 
 
Signed on behalf of the authors:      
 
Form completed by: Caroline Stokes Date: 23.12.10 
 
 
Do the authors have any potential conflict of interest?  Yes  No  
 
If yes, please give details. Authors should declare and describe any present or past affiliations or other 
involvement in any organisation or entity with an interest in the outcome of the review that might lead to a real 
or perceived conflict of interest. This includes acting as an investigator of a study that might be included in 
this review. Authors should declare potential conflicts even if they are confident that their judgement is not 
influenced (see Handbook section 2.6 and www.cochrane.org/docs/commercialsponsorship.htm). 
 
      
 
 
 
Review context 
 
Is the review subject to any specific funding? No 
Is there a deadline for completing the review? No 
Has the review already been completed or 
published elsewhere? 
No 
 
 
Proposed deadlines 
 
Date you plan to submit a draft protocol: (within 4 months) 30 April 2011 (dependent on start date) 
Date you plan to submit a draft review: (within 12 months) 31 December 2011 (dependent on start date) 
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Review authors (see Handbook section 4.2.2.) 
 
Each person named as an author must make a substantial contribution to the conception and design, or 
analysis and interpretation of the data in the review. Please attach a brief cv for each author. 
 
 
 
Contact person / Author 1 (see Handbook section 4.2.3) 
 
Is the contact person an author of the review? Yes  No   
Prefix (e.g. Ms, Dr): Ms Given name (名字 míngzi): Caroline 
Middle initial(s): S Family name (姓 xìng): Stokes 
Suffix (e.g. MD, PhD): RD Web address:       
Preferred full name 
for review byline: 
Stokes CS 
Do you already have a user account and password for the Archie database? Yes  No  
Email address(es): 1) caroline.stokes@uks.eu  
2)       
Job Title/Position: Scientist 
Department: Department of Medicine II 
Organisation: Saarland University Hospital  
Street/Address: Kirrberger Str. 1 
 
City: Homburg Post/Zip code: 66421 
State/Province: Saarland Country: Germany 
Telephone number: +49 6841 16  23299 Fax number: +49 6841 16  23570 
Mobile/cell number:       
Privacy: As the contact person, your address and email will be published with the completed 
protocol or review. Your details will be stored on our central database, known as 
‘Archie’, and may be accessed by members of The Cochrane Collaboration. Details 
of our privacy policy are available at www.cc-ims.net/Archie/archie-privacy-policy. 
Within Archie, would you like to: 
Hide your address and phone numbers:  Hide your email address:  
Country of origin: United Kingdom Gender: Female  Male  
What expertise do you 
bring to the review? 
(e.g. clinical, review methods, statistics)  
 Knowledge of the subject area; experience in scientific writing and publishing 
original and review articles; data collection and synthesis 
 
Have you prepared a systematic review before? Yes  No   
If yes, have you prepared a Cochrane review? (please state most recent title) 
      
Yes  No  
Are you already a member of another Cochrane Review Group? Which one(s)? 
 
Yes  No  
At what level are you able to speak and write English? First language 
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Author 2 
 
You must have at least two authors to register a title. Copy this table for additional authors. 
 
Prefix (e.g. Ms, Dr): Prof Given name (名字 míngzi): Frank 
Middle initial(s):  Family name (姓 xìng): Lammert 
Suffix (e.g. MD, PhD): Dr med Web address:       
Preferred full name 
for review byline: 
Lammert F 
Do you already have a user account and password for the Archie database? Yes  No  
Email address(es): 1) frank.lammert@uks.eu 
2)       
Job Title/Position: Director/Head 
Department: Department of Medicine II 
Organisation: Saarland University Hospital  
Street/Address: Kirrberger Str. 1 
 
City: Homburg Post/Zip code: 66421 
State/Province: Saarland Country: Germany 
Telephone number: +49 6841 16  23201 Fax number: +49 6841 16 23267 
Mobile/cell number:       
Privacy: Your details will be stored on our central database, known as ‘Archie’, and may be 
accessed by members of The Cochrane Collaboration. Details of our privacy policy 
are available at www.cc-ims.net/Archie/archie-privacy-policy. Within Archie, would 
you like to: 
Hide your address and phone numbers:  Hide your email address:  
Country of origin: Germany Gender: Female  Male  
What expertise do you 
bring to the review? 
(e.g. clinical, review methods, statistics)  
In-depth knowledge of the subject area and experience in developing clinical 
practice guidelines, experience of systematic reviews  
Select publications from 2005 onwards: 
Reviews 
1. Lammert F, Sauerbruch T. Molecular mechanisms of disease: the genetic 
epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 
2005; 2 (9): 423-433 [IF 4,4] 
2. Grünhage F, Lammert F. Pathogenesis of gallstones: a genetic perspective. 
Best Pract Res Clin Gastroenterol 2006; 20 (6): 997-1015 [IF 2,1] 
3. Wittenburg H, Lammert F. Genetic predisposition to gallbladder stones. 
Semin Liver Dis 2007; 27 (1): 109-121 [IF 3,8] 
4. Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based 
therapy. J Hepatol 2008; 48 (S1): S124-S135 [IF 7,8] 
5. Höblinger A, Lammert F. Genetics of biliary tract diseases: new insights into 
gallstone disease and biliary tract cancers. Curr Opin Gastroenterol 2008; 
24 (3): 363-371 [IF 3,0] 
6. Krawczyk M, Müllenbach R, Weber S, Zimmer V, Lammert F. Genome-wide 
association studies and genetic risk assessment of liver diseases   Nat Rev 
Gastroenterol Hepatol 2010; 7: 669-681 [IF 4,4] 
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Original Research  
1      Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall  
HU. Genetic and environmental influences on symptomatic gallstone 
disease: a Swedish study of 43141 twin pairs. Hepatology 2005; 41 (5): 
1138-1143 [IF 11,4] 
2. Grünhage F*, Acalovschi M*, Tirziu S, Walier M, Wienker TF, Ciocan A, 
Mosteanu O, Sauerbruch T, Lammert F. Increased gallstone risk in humans 
conferred by common variant of the hepatic ABC transporter for cholesterol. 
Hepatology 2007; 46 (3): 793-801 [IF 11,4] 
3. Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, 
Kluck C, Bäßmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, 
Rosskopf D, Timm B, Höll C, Seeger M, ElSharawy A, Lu T, Egberts J, 
Fändrich F, Fölsch UR, Krawczak M, Schreiber S, Nürnberg P, Tepel J, 
Hampe J. A genome-wide association scan identifies the hepatic cholesterol 
transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat 
Genet 2007; 39 (8): 995-999 [IF 25,6] 
4. Schafmayer C, Völzke H, Buch S, Egberts J, Spille A, von Eberstein H, 
Franke A, Seeger M, Hinz S, ElSharawy A, Rosskopf D, Brosch M, Krawczak 
M, Fölsch UR, Schafmayer A, Lammert F, Schreiber S, Fändrich F, Hampe 
J, Tepel J. Investigation of the Lith6 candidate genes ABOBEC1 and PPARG 
in human symptomatic gallstone disease. Liver Int 2007; 27 (7): 910-919    
[IF 2,6] 
5. Zúñiga S, Molina H, Azocar L, Amigo L, Arrese M, Nervi F, Lammert F, 
Miquel JF. Ezetimibe prevents cholesterol gallstone formation in mice. Liver 
Int 2008; 28 (7): 935-947 [IF 2,6] 
6. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Méndez-Sánchez 
N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mössner J, Lammert F, 
Wittenburg H. Variation of the gene encoding the nuclear bile salt receptor 
FXR and gallstone susceptibility in mice and humans. J Hepatol 2008; 48: 
116-124 [IF 7,8] 
7. Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Grünhage F, Lammert F. 
Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in 
sib pairs with gallstones and controls. Lipids 2009; 44 (6): 521-526 [IF 1,4] 
8. Katsika D, Magnusson P, Krawczyk M, Grünhage F, Lichtenstein P, 
Einarsson C, Lammert F, Marschall HU. Gallstone disease in Swedish twins 
is associated to ABCG8 D19H risk genotype. J Int Med 2010; epub [IF 5,4] 
 
Guidelines 
 
1. Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller 
F, Kiehne KH, Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, 
Sauerbruch T. S3-guidelines for diagnosis and treatment of gallstones. 
German society for digestive and metabolic diseases and german society for 
surgery of the alimentary tract. Z Gastroenterol 2007; 45 (9): 971-1001 [IF 
0,8]  
2. Beuers U, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P, Jones 
DE, Lammert F, Parès A, Trauner M. EASL Clinical Practice Guidelines: 
Management of cholestatic liver diseases. J Hepatol 2009; 51 (2): 237-267 
[IF 7,0] 
Have you prepared a systematic review before? Yes  No   
If yes, have you prepared a Cochrane review? (please state most recent title) 
      
Yes  No  
Are you already a member of another Cochrane Review Group? Which one(s)? 
Cochrane Hepato-Biliary Review Group 
Yes  No  
At what level are you able to speak and write English? Equivalent to a native speaker 
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Roles and responsibilities 
 
Please advise who has agreed to undertake each of the following tasks: 
 
Draft the protocol CS and FL  
Develop and run the search strategy CS and FL with input from the TSC  
Obtain copies of studies CS 
Select which studies to include (2 people) CS and FL 
Extract data from studies (2 people) CS and FL 
Enter data into RevMan CS 
Carry out the analysis CS 
Interpret the analysis CS and FL 
Draft the final review CS and FL 
Update the review CS and FL 
 
Team resources 
 
Have you read the Cochrane Handbook for Systematic Reviews of Interventions? 
(see www.cochrane.org/resources/handbook) 
Yes  No  
Do you require training? 
If yes, on which topics?  For author 1:  
                                      Preparing a systematic review protocol  
                                      Formulating the methods section of the protocol  
                                      Understanding meta-analyses 
Yes  No  
Have you attended a Cochrane review training workshop? 
If no, do you plan to? (see www2.cochrane.org/news/workshops.htm) 
Which workshop did you/will you attend?  
RA1 - Beginning a systematic review protocol (Feb 23 2011, UK)  
RA2 - Methods section of the protocol (Feb 24 2011, UK)  
The workshops in Germany are in the German language, therefore being a UK 
national, the UK Cochrane Centre has agreed for author 1 to attend these 
workshops at the protocol stage.  
Yes  No  
Yes  No  
Which computer operating system do you use? Windows 
Have you downloaded and installed RevMan, the Cochrane review software? 
(see www.cc-ims.net/RevMan) 
Yes  No  
 
Have you seen the Cochrane Hepato-Biliary Review Group website (see 
http://ctu.rh.dk/chbg)? 
Yes  No  
Do you have access to these electronic databases: The Cochrane Library 
MEDLINE 
                                                                                            EMBASE  
Yes  No  
Yes  No  
Yes  No  
Do you have access to a medical library? 
If yes, can you order journal articles not held in the library? 
Yes  No  
Yes  No  
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Do you have access to advice from a medical librarian? 
 
Yes  No  
Do you have access to reference management software (e.g. Endnote)? 
If yes, which software, and what version? Endnote X4 
Yes  No  
 
Do you have access to a statistician? 
If yes, who? 
We have access to statistical/biometric consultancy from the Director PD Dr S 
Gräber of the Institute for Medical Biometry, Epidemiology and Medical Computer 
Science at Saarland University Hospital.  
 
www.uniklinikum-saarland.de/einrichtungen/fachrichtungen-theoretische-und-klinische-
medizin/imbei/wissenschaftliche-kooperation/   
Yes  No  
Do you have contact with consumer groups relevant to this review? 
If yes, which one(s)? 
Patients with identified genetic and environmental risk factors for gallbladder 
stones; patients diagnosed with gallbladder stones  
Yes  No  
Have you identified appropriate time and resources to complete the review? 
The authors plan on seeking guidance from a meta analysis expert for this review. 
Yes  No  
Would you like to be assigned a mentor (an experienced author who has 
volunteered to help new authors)?  
Yes  No  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 156
Acknowledgements 
 
I am extremely grateful to my supervisor, Prof. Dr. Frank Lammert for providing me 
with the opportunity to dabble in the wonderful world of ‘gallstones’ and for his 
unwavering trust, and precious guidance throughout. It has been a real privilege. A 
special thank you to Dr. Lisa Lotte Gluud for her incredible support and inspiration - I 
am tremendously grateful. I would also like to warmly thank Sarah Klingenberg, the 
Cochrane Trial Search Co-ordinator, for carrying out the searches of the electronic 
databases so quickly and efficiently; to Christian Gluud and Dimitrinka Nikolova from 
the Cochrane Hepato-Biliary Group for their support and guidance. I would also like 
to express my gratitude to Nadine Godel for so diligently reviewing the titles from the 
search outcome with me; to Markus Casper for being my ally in the data extraction; to 
Silvia Zuniga and Marcin Krawczyk for their help in translating the Spanish and Italian 
trials and to Alexander Olbricht for coming to the rescue when my computer was 
crashing! I am also very grateful to my family – to my partner Dietrich for his patience, 
understanding and endless support and to my parents Lili and Trevor, my sister 
Debbie and my grandmother Mary for their endless support and encouragement 
throughout. 
Lastly but certainly not least, I would like to thank all the authors of the studies and 
the pharmaceutical companies who kindly responded to my questions and requests 
for more information. I really appreciate you taking the time to reply to my 
burdensome emails! 
 
 
 
 
 
  
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 157
Related Scientific Publications 
 
Krawczyk M*, Stokes CS*, Lammert F. Bile duct stones: new approaches to genetics and 
treatment. Current Opinion in Gastroenterology 2013;29:329-35 *Both authors contributed 
equally 
 
Krawczyk M, Miquel JF, Stokes CS, Hampe J, Balraj M, Lammert F. Genetics of biliary 
lithiasis from an ethnic perspective. Clinics and Research in Hepatology and 
Gastroenterology 2013;37:119-25 
 
Stokes CS, Lammert F. Non-pharmacological and pharmacological interventions for primary 
prevention of gallbladder stones in adults (Protocol). Cochrane Database of Systematic 
Reviews 2012; Issue 6. Art No.: CD009918. DOI: 1002/14651858.CD009918 
 
Stokes CS, Lammert F. Transporters in Cholelithiasis. Biological Chemistry 2012;393:3-10 
 
Stokes CS, Krawczyk M, Lammert F. Gallstones: environment, lifestyle and genes. Digestive 
Diseases 2011;29:191-201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_________________________________________________________________________ 
 
 
__________________________________________________________________________ 
 158
Curriculum Vitae 
 
Education 
 
2008-10  PG DIP (Postgrad. Degree) Clinical Nutrition/Dietetics, King’s College London, UK 
2001-03  MMedSci (Master of Medical Sciences) Human Nutrition, Sheffield University, UK 
1996-99  BSc (Hons) (Bachelor of Science) Psychology, Southampton Solent University, UK 
1992-96  International Baccalaureate, American Community Schools, Athens, Greece 
 
 
Employment 
 
Since 07/10    Clinical Scientist, Saarland University Medical Center, Homburg Germany  
− Doctoral studies/PhD topic: Meta-analysis (Cochrane Review) of 
pharmacological and non-pharmacological interventions for primary 
prevention of gallbladder stones 
− Supervisor: Prof. Dr. med. Frank Lammert, Department of Internal 
Medicine II 
− Research on the role of vitamin D in chronic liver diseases 
− Internal Medicine Teaching Coordinator for Saarland University Medical 
School  
 
01/09-12/09    Nutrition Consultant, Pfizer SMA Nutrition, UK 
01/08-06/08    Nutrition Scientist, British Nutrition Foundation, London, UK 
01/06-12/07    Research Scientist, Medical Research Council, Human Nutrition Research, 
Cambridge, UK 
12/05-12/06 Director, Fareshare South Yorkshire, Barnsley, UK  
02/04-12/06    Research Nutritionist, Doncaster and South Humber National Health 
Service, Sheffield, UK 
 
 
Awards 
 
2012          Saarland University Excellence Programme for scientists striving to be Professors  
2010          Studienstiftung Saar – PhD Stipend  
2010          Van Den Berghs-Prize for most distinguished graduate on clinical nutrition course  
2007          ‘Rising Stars’ Programme in public communication, Cambridge University  
2005          National Health Service (NHS) Journal Award  
2005          Certificate of Commendation from NHS Trust Chief Executive  
